Involvement	O
of	O
phosphatidylinositol	B-protein
3-kinase	I-protein
in	O
NFAT	B-protein
activation	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Phosphatidylinositol	B-protein
3-kinase	I-protein
(	O
PI3-K	B-protein
)	O
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
cell	O
proliferation	O
in	O
many	O
cell	O
types	O
.	O

We	O
have	O
previously	O
shown	O
that	O
in	O
T	B-cell_type
cells	I-cell_type
the	O
PI3-K	B-protein
inhibitor	O
,	O
wortmannin	O
,	O
interferes	O
with	O
activation	O
of	O
the	O
mitogen-activated	B-protein
kinase	I-protein
,	O
Erk2	B-protein
,	O
after	O
T	B-protein
cell	I-protein
receptor	I-protein
(	O
TcR	B-protein
)	O
stimulation	O
.	O

To	O
further	O
explore	O
the	O
involvement	O
of	O
PI3-K	B-protein
in	O
T	O
cell	O
activation	O
,	O
we	O
created	O
a	O
set	O
of	O
potentially	O
dominant	B-DNA
negative	I-DNA
PI3-K	I-DNA
constructs	I-DNA
comprising	O
individual	O
or	O
tandem	B-DNA
domains	I-DNA
of	O
the	O
regulatory	B-protein
p85	I-protein
subunit	I-protein
and	O
tested	O
their	O
effect	O
on	O
downstream	O
signaling	O
events	O
like	O
Erk2	B-protein
activation	O
and	O
transcription	O
from	O
an	O
NFAT	B-DNA
(	I-DNA
nuclear	I-DNA
factor	I-DNA
of	I-DNA
activated	I-DNA
T	I-DNA
cells	I-DNA
)	I-DNA
element	I-DNA
taken	O
from	O
the	O
interleukin-2	B-DNA
promoter	I-DNA
.	O

Following	O
TcR	B-protein
stimulation	O
,	O
activation	O
of	O
Erk2	B-protein
was	O
only	O
inhibited	O
by	O
a	O
previously	O
described	O
truncated	B-protein
form	I-protein
of	I-protein
p85	I-protein
that	O
can	O
not	O
bind	O
the	O
catalytic	B-protein
subunit	I-protein
,	O
but	O
not	O
by	O
other	O
constructs	O
of	O
p85	B-protein
.	O

In	O
contrast	O
,	O
several	O
mutant	O
p85	B-protein
alleles	O
had	O
dramatic	O
effects	O
on	O
NFAT	B-protein
activation	O
.	O

Most	O
interestingly	O
,	O
the	O
N-terminal	B-protein
SH2	I-protein
domain	I-protein
had	O
an	O
inhibitory	O
effect	O
,	O
whereas	O
a	O
mutant	B-protein
p85	I-protein
containing	O
only	O
the	O
two	B-protein
SH2	I-protein
domains	I-protein
enhanced	O
basal	O
NFAT	B-protein
activity	O
in	O
a	O
Ras	B-protein
-dependent	O
manner	O
.	O

Ionomycin	O
induced	O
synergistic	O
activation	O
of	O
NFAT	B-protein
in	O
cells	O
expressing	O
p85	B-protein
mutants	I-protein
that	O
contained	O
the	O
C-terminal	B-protein
SH2	I-protein
domain	I-protein
.	O

Analysis	O
of	O
phosphotyrosine-containing	B-protein
proteins	I-protein
bound	O
to	O
truncated	O
p85	B-protein
constructs	I-protein
revealed	O
cooperative	O
binding	O
of	O
the	O
two	B-protein
SH2	I-protein
domains	I-protein
but	O
no	O
apparent	O
differences	O
between	O
the	O
N-	B-protein
and	I-protein
C-	I-protein
terminal	I-protein
SH2	I-protein
domains	I-protein
.	O

Wortmannin	O
did	O
not	O
interfere	O
with	O
NFAT	B-protein
activation	O
,	O
although	O
it	O
inhibited	O
PI3-K	B-protein
and	O
Erk2	B-protein
activation	O
in	O
the	O
same	O
experiment	O
.	O

These	O
results	O
suggest	O
that	O
PI3-K	B-protein
is	O
involved	O
in	O
NFAT	B-protein
activation	O
through	O
a	O
complex	O
adaptor	O
function	O
of	O
its	O
regulatory	B-protein
subunit	I-protein
and	O
that	O
its	O
lipid	B-protein
kinase	I-protein
activity	O
is	O
dispensable	O
for	O
this	O
effect	O
.	O

THE	NULL
JOURNAL	NULL
or	NULL
BIOLOGICAL	NULL
CHEMISTRY	NULL
Â©	NULL
1997	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
for	NULL
Biochemistry	NULL
and	NULL
Molecular	NULL
Biology	NULL
,	NULL
Inc.	NULL
Vol	NULL
.	NULL

272	NULL
,	NULL
No	NULL
.	NULL

22	NULL
,	NULL
Issue	NULL
of	NULL
May	NULL
30	NULL
,	NULL
pp	NULL
.	NULL

14483-14488	NULL
,	NULL
1997	NULL
Printed	NULL
in	NULL
U.S.A.	NULL
Involvement	NULL
of	NULL
Phosphatidylinositol	NULL
3-Kinase	NULL
in	NULL
NFAT	NULL
Activation	NULL
in	NULL
T	NULL
Cells*	NULL
(	NULL
Received	NULL
for	NULL
publication	NULL
,	NULL
January	NULL
28	NULL
,	NULL
1997	NULL
)	NULL
Thomas	NULL
Jascur	NULL
,	NULL
Jennifer	NULL
Gilman	NULL
,	NULL
and	NULL
Tomas	NULL
Mustelint	NULL
From	NULL
the	NULL
Division	NULL
of	NULL
Cell	NULL
Biology	NULL
,	NULL
La	NULL
Jolla	NULL
Institute	NULL
for	NULL
Allergy	NULL
and	NULL
Immunology	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
California	NULL
92121	NULL
Phosphatidylinositol	NULL
3-kinase	NULL
(	NULL
PI3-K	NULL
)	NULL
has	NULL
been	NULL
implicated	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
cell	NULL
proliferation	NULL
in	NULL
many	NULL
cell	NULL
types	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
shown	NULL
that	NULL
in	NULL
T	NULL
cells	NULL
the	NULL
PI3-K	NULL
inhibitor	NULL
,	NULL
wortmannin	NULL
,	NULL
interferes	NULL
with	NULL
activation	NULL
of	NULL
the	NULL
mitogen-activated	NULL
kinase	NULL
,	NULL
Erk2	NULL
,	NULL
after	NULL
T	NULL
cell	NULL
receptor	NULL
(	NULL
TeR	NULL
)	NULL
stimulation	NULL
.	NULL

To	NULL
further	NULL
explore	NULL
the	NULL
involvement	NULL
of	NULL
in	NULL
T	NULL
cell	NULL
activation	NULL
,	NULL
we	NULL
created	NULL
a	NULL
set	NULL
of	NULL
potentially	NULL
dominant	NULL
negative	NULL
PI3-K	NULL
constructs	NULL
comprising	NULL
individual	NULL
or	NULL
tandem	NULL
domains	NULL
of	NULL
the	NULL
regulatory	NULL
p85	NULL
subunit	NULL
and	NULL
tested	NULL
their	NULL
effect	NULL
on	NULL
downstream	NULL
signaling	NULL
events	NULL
like	NULL
Erk2	NULL
activation	NULL
and	NULL
transcription	NULL
from	NULL
an	NULL
NFAT	NULL
(	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
)	NULL
element	NULL
taken	NULL
from	NULL
the	NULL
interleukin-2	NULL
promoter	NULL
.	NULL

Following	NULL
TcR	NULL
stimulation	NULL
,	NULL
activation	NULL
of	NULL
Erk2	NULL
was	NULL
only	NULL
inhibited	NULL
by	NULL
a	NULL
previously	NULL
described	NULL
truncated	NULL
form	NULL
of	NULL
p85	NULL
that	NULL
can	NULL
not	NULL
bind	NULL
the	NULL
catalytic	NULL
subunit	NULL
,	NULL
but	NULL
not	NULL
by	NULL
other	NULL
constructs	NULL
of	NULL
p85	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
several	NULL
mutant	NULL
p85	NULL
alleles	NULL
had	NULL
dramatic	NULL
effects	NULL
on	NULL
NFAT	NULL
activation	NULL
.	NULL

Most	NULL
interest-ingly	NULL
,	NULL
the	NULL
N-terminal	NULL
SH2	NULL
domain	NULL
had	NULL
an	NULL
inhibitory	NULL
ef-fect	NULL
,	NULL
whereas	NULL
a	NULL
mutant	NULL
p85	NULL
containing	NULL
only	NULL
the	NULL
two	NULL
SH2	NULL
domains	NULL
enhanced	NULL
basal	NULL
NFAT	NULL
activity	NULL
in	NULL
a	NULL
Ras-depend-ent	NULL
manner	NULL
.	NULL

Ionomycin	NULL
induced	NULL
synergistic	NULL
activation	NULL
of	NULL
NFAT	NULL
in	NULL
cells	NULL
expressing	NULL
p85	NULL
mutants	NULL
that	NULL
contained	NULL
the	NULL
C-terminal	NULL
SH2	NULL
domain	NULL
.	NULL

Analysis	NULL
of	NULL
phosphotyrosine-containing	NULL
proteins	NULL
bound	NULL
to	NULL
truncated	NULL
p85	NULL
constructs	NULL
revealed	NULL
cooperative	NULL
binding	NULL
of	NULL
the	NULL
two	NULL
SH2	NULL
domains	NULL
but	NULL
no	NULL
apparent	NULL
differences	NULL
between	NULL
the	NULL
N-	NULL
and	NULL
C-terminal	NULL
SH2	NULL
domains	NULL
.	NULL

Wortmannin	NULL
did	NULL
not	NULL
interfere	NULL
with	NULL
NFAT	NULL
activation	NULL
,	NULL
although	NULL
it	NULL
inhibited	NULL
PI3-K	NULL
and	NULL
Erk2	NULL
activation	NULL
in	NULL
the	NULL
same	NULL
experiment	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
PI3-K	NULL
is	NULL
involved	NULL
in	NULL
NFAT	NULL
activation	NULL
through	NULL
a	NULL
complex	NULL
adaptor	NULL
function	NULL
of	NULL
its	NULL
regulatory	NULL
subunit	NULL
and	NULL
that	NULL
its	NULL
lipid	NULL
kinase	NULL
activity	NULL
is	NULL
dispensable	NULL
for	NULL
this	NULL
effect	NULL
.	NULL

Phosphatidylinositol	NULL
3-kinase	NULL
(	NULL
PI8-K	NULL
)	NULL
'	NULL
has	NULL
been	NULL
implicated	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
cell	NULL
growth	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
cell	NULL
types	NULL
including	NULL
T	NULL
lymphocytes	NULL
(	NULL
1	NULL
)	NULL
.	NULL

Engagement	NULL
of	NULL
the	NULL
T	NULL
cell	NULL
antigen	NULL
receptor	NULL
(	NULL
TeR	NULL
)	NULL
causes	NULL
an	NULL
increase	NULL
in	NULL
the	NULL
intracellular	NULL
levels	NULL
of	NULL
the	NULL
PI3-K	NULL
reaction	NULL
products	NULL
,	NULL
phosphatidylinositol	NULL
3,4-bisphos-	NULL
*	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
Grants	NULL
AI35603	NULL
and	NULL
GM48960	NULL
and	NULL
by	NULL
a	NULL
fellowship	NULL
from	NULL
the	NULL
Swiss	NULL
National	NULL
Science	NULL
Foundation	NULL
(	NULL
to	NULL
T	NULL
.	NULL

J	NULL
.	NULL
)	NULL

.	NULL

This	NULL
is	NULL
publication	NULL
173	NULL
from	NULL
the	NULL
Lia	NULL
Jolla	NULL
Institute	NULL
for	NULL
Allergy	NULL
and	NULL
Immunology	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

{	NULL
To	NULL
whom	NULL
correspondence	NULL
should	NULL
be	NULL
addressed	NULL
:	NULL
Division	NULL
of	NULL
Cell	NULL
Biology	NULL
,	NULL
La	NULL
Jolla	NULL
Institute	NULL
for	NULL
Allergy	NULL
and	NULL
Immunology	NULL
,	NULL
10855	NULL
Science	NULL
Center	NULL
Dr.	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
92121	NULL
.	NULL

Tel	NULL
.	NULL

:	NULL
619-558-8547	NULL
;	NULL
Fax	NULL
:	NULL
619-558-3526	NULL
;	NULL
E-mail	NULL
:	NULL
tomas	NULL
_mustelin	NULL
@	NULL
liai.org	NULL
.	NULL

*	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
PIS-K	NULL
,	NULL
phosphatidylinositol	NULL
8-kinase	NULL
;	NULL
TeR	NULL
,	NULL
T	NULL
cell	NULL
antigen	NULL
receptor	NULL
;	NULL
NFAT	NULL
,	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
;	NULL
PMA	NULL
,	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
;	NULL
SH	NULL
,	NULL
Sre	NULL
homology	NULL
;	NULL
iSH	NULL
,	NULL
inter-SH	NULL
;	NULL
mAb	NULL
,	NULL
monoclonal	NULL
antibody	NULL
;	NULL
PKC	NULL
,	NULL
protein	NULL
kinase	NULL
C	NULL
;	NULL
HA	NULL
antigen	NULL
.	NULL

This	NULL
paper	NULL
is	NULL
available	NULL
on	NULL
line	NULL
at	NULL
http	NULL
:	NULL
//www-jbc.stanford.edu/jbc/	NULL
phate	NULL
,	NULL
and	NULL
phosphatidylinositol	NULL
3,4,5-trisphosphate	NULL
(	NULL
2	NULL
)	NULL
.	NULL

These	NULL
lipids	NULL
are	NULL
not	NULL
subject	NULL
to	NULL
breakdown	NULL
by	NULL
phospholipase	NULL
C	NULL
but	NULL
seem	NULL
to	NULL
activate	NULL
Ser/Thr-specific	NULL
protein	NULL
kinases	NULL
such	NULL
as	NULL
some	NULL
isoforms	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
(	NULL
3-5	NULL
)	NULL
,	NULL
and	NULL
protein	NULL
kinase	NULL
B	NULL
,	NULL
also	NULL
known	NULL
as	NULL
c-Akt	NULL
(	NULL
6	NULL
,	NULL
7	NULL
)	NULL
.	NULL

The	NULL
isoform	NULL
of	NULL
PIS-K	NULL
that	NULL
becomes	NULL
activated	NULL
in	NULL
response	NULL
to	NULL
growth	NULL
factor	NULL
receptor	NULL
stimulation	NULL
is	NULL
a	NULL
heterodimeric	NULL
enzyme	NULL
consisting	NULL
of	NULL
an	NULL
85-kDa	NULL
regulatory	NULL
subunit	NULL
(	NULL
p85	NULL
Â«	NULL
or	NULL
p85	NULL
$	NULL
B	NULL
)	NULL
(	NULL
8-10	NULL
)	NULL
and	NULL
a	NULL
110-kDa	NULL
catalytic	NULL
subunit	NULL
(	NULL
p110a	NULL
or	NULL
(	NULL
11	NULL
)	NULL
.	NULL

The	NULL
p85	NULL
subunit	NULL
contains	NULL
a	NULL
number	NULL
of	NULL
domains	NULL
that	NULL
mediate	NULL
protein-protein	NULL
interactions	NULL
and	NULL
are	NULL
commonly	NULL
found	NULL
in	NULL
signaling	NULL
proteins	NULL
:	NULL
one	NULL
Sre	NULL
homology	NULL
3	NULL
(	NULL
SH3	NULL
)	NULL
domain	NULL
,	NULL
two	NULL
proline-rich	NULL
regions	NULL
,	NULL
two	NULL
SH2	NULL
domains	NULL
,	NULL
and	NULL
a	NULL
region	NULL
with	NULL
similarity	NULL
to	NULL
the	NULL
breakpoint	NULL
cluster	NULL
region	NULL
gene	NULL
(	NULL
BCR	NULL
homology	NULL
region	NULL
)	NULL
.	NULL

Binding	NULL
of	NULL
the	NULL
catalytic	NULL
p110	NULL
subunit	NULL
occurs	NULL
through	NULL
interaction	NULL
of	NULL
the	NULL
region	NULL
between	NULL
the	NULL
SH2	NULL
domains	NULL
of	NULL
p85	NULL
(	NULL
inter-SH2	NULL
domain	NULL
or	NULL
iSH2	NULL
)	NULL
and	NULL
the	NULL
extreme	NULL
N	NULL
terminus	NULL
of	NULL
the	NULL
catalytic	NULL
subunit	NULL
(	NULL
12	NULL
,	NULL
13	NULL
)	NULL
.	NULL

Regulation	NULL
of	NULL
PI3-K	NULL
activity	NULL
occurs	NULL
through	NULL
interaction	NULL
of	NULL
the	NULL
two	NULL
subunits	NULL
(	NULL
14	NULL
,	NULL
15	NULL
)	NULL
,	NULL
autophosphorylation	NULL
at	NULL
Ser-608	NULL
(	NULL
16	NULL
)	NULL
,	NULL
and	NULL
membrane	NULL
localization	NULL
(	NULL
17	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
a	NULL
number	NULL
of	NULL
reports	NULL
have	NULL
demonstrated	NULL
that	NULL
binding	NULL
of	NULL
cellular	NULL
proteins	NULL
to	NULL
PI3-K	NULL
domains	NULL
can	NULL
increase	NULL
its	NULL
enzymatic	NULL
activity	NULL
:	NULL
the	NULL
SH3	NULL
domain	NULL
of	NULL
Sre	NULL
family	NULL
kinases	NULL
binding	NULL
to	NULL
one	NULL
or	NULL
both	NULL
of	NULL
the	NULL
proline-rich	NULL
regions	NULL
of	NULL
p85	NULL
(	NULL
18	NULL
)	NULL
,	NULL
phosphotyrosine-containing	NULL
peptides	NULL
binding	NULL
to	NULL
the	NULL
SH2	NULL
domains	NULL
of	NULL
p85	NULL
(	NULL
19	NULL
,	NULL
20	NULL
)	NULL
,	NULL
and	NULL
GTP-Ras	NULL
binding	NULL
to	NULL
the	NULL
catalytic	NULL
pl110	NULL
subunit	NULL
(	NULL
21	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
in	NULL
vivo	NULL
function	NULL
of	NULL
these	NULL
and	NULL
the	NULL
other	NULL
PI3-K	NULL
domains	NULL
,	NULL
and	NULL
their	NULL
contribution	NULL
to	NULL
various	NULL
signaling	NULL
processes	NULL
of	NULL
PI3-K	NULL
,	NULL
are	NULL
poorly	NULL
understood	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
shown	NULL
that	NULL
TceR-induced	NULL
activation	NULL
of	NULL
the	NULL
mitogen-activated	NULL
kinase	NULL
,	NULL
Erk2	NULL
,	NULL
requires	NULL
PI3-K	NULL
activity	NULL
since	NULL
the	NULL
PI3-K	NULL
inhibitor	NULL
,	NULL
wortmannin	NULL
,	NULL
blocked	NULL
Erk2	NULL
activation	NULL
(	NULL
22	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
a	NULL
mutated	NULL
form	NULL
of	NULL
p85	NULL
that	NULL
lacked	NULL
the	NULL
p110-binding	NULL
iSH2	NULL
region	NULL
(	NULL
p85A1iSH2	NULL
)	NULL
reduced	NULL
Erk2	NULL
activation	NULL
,	NULL
presumably	NULL
by	NULL
occupying	NULL
PI3-K	NULL
binding	NULL
sites	NULL
on	NULL
other	NULL
cellular	NULL
proteins	NULL
.	NULL

To	NULL
study	NULL
this	NULL
in	NULL
more	NULL
detail	NULL
and	NULL
to	NULL
shed	NULL
some	NULL
light	NULL
on	NULL
the	NULL
physiological	NULL
role	NULL
of	NULL
the	NULL
various	NULL
domains	NULL
,	NULL
we	NULL
have	NULL
generated	NULL
a	NULL
set	NULL
of	NULL
truncated	NULL
p85	NULL
mutants	NULL
to	NULL
study	NULL
the	NULL
role	NULL
of	NULL
PI3-K.	NULL
domains	NULL
in	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

As	NULL
a	NULL
functional	NULL
readout	NULL
we	NULL
used	NULL
a	NULL
reporter	NULL
gene	NULL
driven	NULL
by	NULL
the	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
NFAT	NULL
)	NULL
,	NULL
which	NULL
is	NULL
a	NULL
transcription	NULL
factor	NULL
complex	NULL
that	NULL
plays	NULL
a	NULL
key	NULL
role	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
the	NULL
interleukin-2	NULL
gene	NULL
and	NULL
other	NULL
lymphokine	NULL
genes	NULL
during	NULL
T	NULL
cell	NULL
activation	NULL
(	NULL
23	NULL
)	NULL
.	NULL

It	NULL
consists	NULL
of	NULL
two	NULL
components	NULL
:	NULL
preexisting	NULL
cytosolic	NULL
NFATp	NULL
,	NULL
which	NULL
translocates	NULL
into	NULL
the	NULL
nucleus	NULL
in	NULL
response	NULL
to	NULL
a	NULL
calcium	NULL
signal	NULL
,	NULL
and	NULL
a	NULL
nuclear	NULL
component	NULL
,	NULL
AP-1	NULL
,	NULL
which	NULL
consists	NULL
of	NULL
c-Fos	NULL
and	NULL
c-Jun	NULL
proteins	NULL
and	NULL
is	NULL
induced	NULL
by	NULL
a	NULL
cascade	NULL
of	NULL
mitogen-activated	NULL
protein	NULL
kinase-related	NULL
protein	NULL
kinases	NULL
and	NULL
as	NULL
a	NULL
result	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
activation	NULL
.	NULL

NFAT-driven	NULL
expression	NULL
of	NULL
reporter	NULL
genes	NULL
has	NULL
been	NULL
widely	NULL
used	NULL
as	NULL
a	NULL
physiologically	NULL
relevant	NULL
assay	NULL
to	NULL
study	NULL
signal	NULL
trans-duction	NULL
events	NULL
that	NULL
lead	NULL
to	NULL
cytokine	NULL
expression	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Here	NULL
we	NULL
report	NULL
that	NULL
PI3-K	NULL
has	NULL
different	NULL
effects	NULL
on	NULL
Erk2	NULL
and	NULL
downstream	NULL
14483	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
/810-0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wo	NULL
;	NULL
popeoumog	NULL
14484	NULL
NFAT	NULL
activation	NULL
.	NULL

Erk2	NULL
activation	NULL
in	NULL
response	NULL
to	NULL
TcR	NULL
engagement	NULL
was	NULL
sensitive	NULL
to	NULL
wortmannin	NULL
,	NULL
and	NULL
only	NULL
inhibited	NULL
by	NULL
over-expressing	NULL
p85AiSH2	NULL
,	NULL
but	NULL
not	NULL
individual	NULL
p85	NULL
domains	NULL
.	NULL

NFAT	NULL
activation	NULL
,	NULL
on	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
was	NULL
not	NULL
sensitive	NULL
to	NULL
wortmannin	NULL
,	NULL
but	NULL
was	NULL
inhibited	NULL
by	NULL
the	NULL
SH3	NULL
domain	NULL
,	NULL
the	NULL
N-terminal	NULL
SH2	NULL
domain	NULL
,	NULL
and	NULL
a	NULL
p85	NULL
fragment	NULL
comprising	NULL
the	NULL
two	NULL
proline-rich	NULL
regions	NULL
and	NULL
the	NULL
BCR	NULL
homology	NULL
domain	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
three	NULL
constructs	NULL
that	NULL
contain	NULL
the	NULL
C-terminal	NULL
SH2	NULL
domain	NULL
caused	NULL
an	NULL
elevated	NULL
basal	NULL
level	NULL
of	NULL
NFAT	NULL
activity	NULL
,	NULL
which	NULL
was	NULL
synergisti-cally	NULL
increased	NULL
by	NULL
ionomycin	NULL
.	NULL

Both	NULL
the	NULL
increased	NULL
basal	NULL
NFAT	NULL
level	NULL
and	NULL
the	NULL
activation	NULL
following	NULL
TcR	NULL
stimulation	NULL
depended	NULL
on	NULL
functional	NULL
Ras	NULL
and	NULL
calcineurin	NULL
.	NULL

These	NULL
studies	NULL
provide	NULL
evidence	NULL
that	NULL
PI3-K	NULL
is	NULL
involved	NULL
in	NULL
cytokine	NULL
induction	NULL
in	NULL
a	NULL
way	NULL
that	NULL
does	NULL
not	NULL
involve	NULL
enzymatic	NULL
activity	NULL
but	NULL
a	NULL
previously	NULL
unrecognized	NULL
adaptor	NULL
function	NULL
of	NULL
the	NULL
regulatory	NULL
subunit	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Antibodies	NULL
and	NULL
Reagents-The	NULL
anti-CD8e	NULL
mAb	NULL
,	NULL
OKT83	NULL
,	NULL
was	NULL
purified	NULL
from	NULL
ascites	NULL
fluid	NULL
by	NULL
protein	NULL
A-Sepharose	NULL
chromatography	NULL
.	NULL

mAb	NULL
4G10	NULL
(	NULL
anti-phosphotyrosine	NULL
)	NULL
and	NULL
anti-p85	NULL
rabbit	NULL
serum	NULL
were	NULL
from	NULL
Upstate	NULL
Biotechnology	NULL
,	NULL
Inc.	NULL
(	NULL
Lake	NULL
Placid	NULL
,	NULL
NY	NULL
)	NULL
.	NULL

Anti-HA	NULL
epitope	NULL
mAb	NULL
12CA5	NULL
was	NULL
from	NULL
Boehringer	NULL
Mannheim	NULL
(	NULL
Indianapolis	NULL
,	NULL
IN	NULL
)	NULL
.	NULL

Anti-Eirk2	NULL
polyclonal	NULL
antibodies	NULL
were	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
Inc.	NULL
(	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

The	NULL
c-Myc-tagged	NULL
Erk2	NULL
cDNA	NULL
was	NULL
from	NULL
Dr.	NULL
C.	NULL
Marshall	NULL
(	NULL
Ludwig	NULL
Institute	NULL
for	NULL
Cancer	NULL
Research	NULL
)	NULL
.	NULL

The	NULL
c-Myc	NULL
epitope	NULL
is	NULL
recognized	NULL
by	NULL
mAb	NULL
9E10	NULL
.	NULL

Anti-phospho-Eirk2	NULL
antibody	NULL
was	NULL
from	NULL
New	NULL
England	NULL
Biolabs	NULL
,	NULL
Inc.	NULL
(	NULL
Beverly	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

The	NULL
luciferase	NULL
reporter	NULL
plasmid	NULL
,	NULL
NFAT-luc	NULL
,	NULL
was	NULL
a	NULL
generous	NULL
gift	NULL
from	NULL
Dr.	NULL
G.	NULL
Crabtree	NULL
.	NULL

Luciferin	NULL
was	NULL
from	NULL
Analytical	NULL
Luminescence	NULL
Laboratory	NULL
(	NULL
Ann	NULL
Arbor	NULL
,	NULL
MI	NULL
)	NULL
.	NULL

PI3-K	NULL
Constructs-The	NULL
p85AiSH2	NULL
and	NULL
iSH2	NULL
constructs	NULL
have	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
22	NULL
)	NULL
.	NULL

p85	NULL
fragments	NULL
encoding	NULL
the	NULL
amino	NULL
acids	NULL
indicated	NULL
in	NULL
Fig	NULL
.	NULL

1A	NULL
were	NULL
amplified	NULL
by	NULL
polymerase	NULL
chain	NULL
reaction	NULL
using	NULL
primers	NULL
tailed	NULL
with	NULL
Xbal	NULL
and	NULL
EcoRI	NULL
(	NULL
SH3	NULL
,	NULL
PBP	NULL
,	NULL
N-SH2	NULL
)	NULL
,	NULL
EcoRI	NULL
and	NULL
Ndel	NULL
(	NULL
C-SH2	NULL
)	NULL
,	NULL
or	NULL
Xbal	NULL
and	NULL
Ndel	NULL
(	NULL
NC	NULL
,	NULL
NiC	NULL
,	NULL
full-length	NULL
p85	NULL
)	NULL
sites	NULL
.	NULL

p85AiSH2	NULL
was	NULL
used	NULL
as	NULL
a	NULL
template	NULL
for	NULL
NC	NULL
;	NULL
wild-type	NULL
bovine	NULL
p85	NULL
Â«	NULL
was	NULL
used	NULL
as	NULL
a	NULL
template	NULL
for	NULL
the	NULL
other	NULL
constructs	NULL
.	NULL

The	NULL
N-terminal	NULL
fragment	NULL
of	NULL
pl10	NULL
(	NULL
amino	NULL
acids	NULL
1-171	NULL
)	NULL
was	NULL
amplified	NULL
using	NULL
bovine	NULL
p110a	NULL
as	NULL
a	NULL
template	NULL
and	NULL
primers	NULL
tailed	NULL
with	NULL
NReI	NULL
and	NULL
Ndel	NULL
sites	NULL
.	NULL

The	NULL
fragments	NULL
were	NULL
digested	NULL
with	NULL
the	NULL
appropriate	NULL
restriction	NULL
enzymes	NULL
and	NULL
ligated	NULL
into	NULL
the	NULL
vector	NULL
pEF-HA	NULL
(	NULL
22	NULL
)	NULL
.	NULL

The	NULL
resulting	NULL
fusion	NULL
proteins	NULL
express	NULL
an	NULL
influenza	NULL
hemagglutinin	NULL
epitope	NULL
YPYDVPDYA	NULL
at	NULL
their	NULL
N	NULL
terminus	NULL
.	NULL

All	NULL
constructs	NULL
prepared	NULL
for	NULL
this	NULL
study	NULL
were	NULL
verified	NULL
by	NULL
sequencing	NULL
.	NULL

Cells	NULL
and	NULL
Transient	NULL
Transfections-Jurkat	NULL
cells	NULL
stably	NULL
expressing	NULL
the	NULL
simian	NULL
virus	NULL
large	NULL
T	NULL
antigen	NULL
(	NULL
J-TAg	NULL
)	NULL
were	NULL
kept	NULL
at	NULL
logarithmic	NULL
growth	NULL
in	NULL
RPMI	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
heat-inactivated	NULL
fetal	NULL
calf	NULL
serum	NULL
,	NULL
glutamine	NULL
,	NULL
antibiotics	NULL
,	NULL
and	NULL
0.5	NULL
mg/ml	NULL
G418	NULL
.	NULL

Transient	NULL
transfec-tions	NULL
were	NULL
carried	NULL
out	NULL
by	NULL
electroporation	NULL
as	NULL
described	NULL
before	NULL
(	NULL
22	NULL
)	NULL
.	NULL

Typically	NULL
,	NULL
a	NULL
total	NULL
amount	NULL
of	NULL
DNA	NULL
of	NULL
17-20	NULL
ug	NULL
was	NULL
added	NULL
to	NULL
20	NULL
X	NULL
10Â°	NULL
cells	NULL
(	NULL
5	NULL
ug	NULL
of	NULL
c-Imyc-tagged	NULL
Erk2	NULL
plus	NULL
15	NULL
ug	NULL
of	NULL
PIS-K	NULL
construct	NULL
or	NULL
empty	NULL
vector	NULL
,	NULL
or	NULL
2	NULL
ug	NULL
of	NULL
NFAT-lue	NULL
plus	NULL
15	NULL
ug	NULL
of	NULL
PIS-K	NULL
construct	NULL
or	NULL
empty	NULL
vector	NULL
)	NULL
.	NULL

Immunoprecipitations	NULL
and	NULL
in	NULL
Vitro	NULL
Kinase	NULL
Assays-These	NULL
were	NULL
performed	NULL
essentially	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
22	NULL
)	NULL
.	NULL

Luciferase	NULL
Assays-Two	NULL
days	NULL
after	NULL
transient	NULL
transfection	NULL
,	NULL
J-TAg	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
10	NULL
ug/ml	NULL
OKT3	NULL
,	NULL
50	NULL
ng/ml	NULL
PMA	NULL
,	NULL
or	NULL
1	NULL
ug/ml	NULL
ionomycin	NULL
,	NULL
or	NULL
left	NULL
untreated	NULL
for	NULL
3-4	NULL
h	NULL
in	NULL
24-well	NULL
plates	NULL
in	NULL
a	NULL
tissue	NULL
culture	NULL
incubator	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
washed	NULL
with	NULL
phosphate-buffered	NULL
saline	NULL
and	NULL
lysed	NULL
in	NULL
100	NULL
ul	NULL
of	NULL
lysis	NULL
buffer	NULL
(	NULL
100	NULL
mM	NULL
KPO	NULL
,	NULL
,	NULL
pH	NULL
7.8	NULL
,	NULL
1	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
0.2	NULL
%	NULL
Triton	NULL
X-100	NULL
)	NULL
.	NULL

Lysates	NULL
were	NULL
clarified	NULL
by	NULL
centrifuga-tion	NULL
at	NULL
15,000	NULL
X	NULL
g	NULL
for	NULL
5	NULL
min	NULL
,	NULL
and	NULL
50	NULL
ul	NULL
were	NULL
used	NULL
for	NULL
luciferase	NULL
assays	NULL
in	NULL
an	NULL
automated	NULL
luminometer	NULL
(	NULL
Monolight	NULL
2010	NULL
,	NULL
Analytical	NULL
Luminescence	NULL
Laboratory	NULL
,	NULL
Ann	NULL
Arbor	NULL
,	NULL
MI	NULL
)	NULL
.	NULL

The	NULL
final	NULL
assay	NULL
contained	NULL
50	NULL
pl	NULL
of	NULL
lysate	NULL
plus	NULL
100	NULL
pl	NULL
of	NULL
ATP	NULL
solution	NULL
(	NULL
10	NULL
mM	NULL
ATP	NULL
,	NULL
85	NULL
mM	NULL
glyeyl-glycine	NULL
,	NULL
pH	NULL
7.8	NULL
,	NULL
20	NULL
mm	NULL
MgCl	NULL
,	NULL
)	NULL
plus	NULL
100	NULL
pl	NULL
of	NULL
luciferin	NULL
reagent	NULL
(	NULL
0.27	NULL
mM	NULL
coen-zyme	NULL
A	NULL
,	NULL
0.47	NULL
mM	NULL
luciferin	NULL
,	NULL
85	NULL
mM	NULL
glycyl-glycine	NULL
,	NULL
pH	NULL
7.8	NULL
,	NULL
20	NULL
mm	NULL
MgCl	NULL
,	NULL
,	NULL
)	NULL
.	NULL

The	NULL
protein	NULL
concentration	NULL
in	NULL
the	NULL
cell	NULL
lysates	NULL
was	NULL
determined	NULL
by	NULL
the	NULL
Bradford	NULL
protein	NULL
assay	NULL
and	NULL
used	NULL
to	NULL
normalize	NULL
the	NULL
luciferase	NULL
activity	NULL
.	NULL

Typically	NULL
,	NULL
the	NULL
variation	NULL
in	NULL
protein	NULL
concentration	NULL
between	NULL
samples	NULL
was	NULL
smaller	NULL
than	NULL
20	NULL
%	NULL
.	NULL

RESULTS	NULL
Effect	NULL
of	NULL
PI3-K	NULL
Constructs	NULL
on	NULL
Erk2	NULL
Activation-Among	NULL
the	NULL
signaling	NULL
components	NULL
thought	NULL
to	NULL
be	NULL
downstream	NULL
of	NULL
the	NULL
TcR	NULL
and	NULL
PI3-K	NULL
is	NULL
the	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
,	NULL
Erk2	NULL
(	NULL
24	NULL
)	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
shown	NULL
that	NULL
the	NULL
PI3-K	NULL
inhibitor	NULL
,	NULL
wortmannin	NULL
,	NULL
PI3-K	NULL
in	NULL
NFAT	NULL
Activation	NULL
A	NULL
p110	NULL
binding	NULL
endogenous	NULL
_	NULL
Bor	NULL
Pro	NULL
N-SH2	NULL
-	NULL
(	NULL
inter-SH2	NULL
)	NULL
CS2	NULL
p85	NULL
___	NULL
{	NULL
L-L______	NULL
--	NULL
Â¢	NULL
___	NULL
_E	NULL
__	NULL
___	NULL
j-	NULL
}	NULL
1	NULL
78	NULL
sH3	NULL
AL_	NULL
]	NULL
79	NULL
328	NULL
ProBerPro	NULL
(	NULL
PBP	NULL
)	NULL
}	NULL
{	NULL
{	NULL
=	NULL
[	NULL
_-_____	NULL
}	NULL
-=	NULL
[	NULL
}	NULL
mens	NULL
329	NULL
439	NULL
563	NULL
724	NULL
C-SH2	NULL
___	NULL
Ja	NULL
329	NULL
439	NULL
563	NULL
724	NULL
NC	NULL
wâJ	NULL
329	NULL
724	NULL
wic	NULL
1	NULL
a39	NULL
563	NULL
724	NULL
985AiSH2OCIDâ1ZIâIZI\/âl	NULL
:	NULL
|-425	NULL
616	NULL
s	NULL
1	NULL
724	NULL
p85	NULL
i=l	NULL
femme	NULL
p	NULL
(	NULL
O	NULL
HAtag	NULL
)	NULL
(	NULL
CV	NULL
Â£	NULL
Q	NULL
4	NULL
to	NULL
x0	NULL
x8	NULL
x~	NULL
w	NULL
0	NULL
C	NULL
C	NULL
L	NULL
JS	NULL
Â§	NULL
g	NULL
#	NULL
Â£	NULL
OKT3	NULL
-	NULL
+	NULL
$	NULL
o	NULL
8	NULL
#	NULL
-	NULL
%	NULL
+-	NULL
o	NULL
%	NULL
$	NULL
o	NULL
40	NULL
-	NULL
4	NULL
116	NULL
Â£4	NULL
ge	NULL
f	NULL
Â«	NULL
an	NULL
came	NULL
-	NULL
66	NULL
hhhhh	NULL
~~~	NULL
**	NULL
dkdih	NULL
~	NULL
as	NULL
HA	NULL
blot	NULL
~-	NULL
<	NULL
P	NULL
Â«	NULL
ae	NULL
aas	NULL
am	NULL
__	NULL
m	NULL
P	NULL
-	NULL
2	NULL
Â«	NULL
t	NULL
umn	NULL
tie	NULL
:	NULL
mee	NULL
FiG	NULL
.	NULL

1	NULL
.	NULL

A	NULL
,	NULL
schematic	NULL
representation	NULL
of	NULL
recombinant	NULL
p85	NULL
PI3-K	NULL
constructs	NULL
used	NULL
in	NULL
this	NULL
study	NULL
.	NULL

B	NULL
,	NULL
J-TAg	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
20	NULL
ug	NULL
of	NULL
the	NULL
indicated	NULL
p85	NULL
mutants	NULL
or	NULL
empty	NULL
vector	NULL
.	NULL

After	NULL
2	NULL
days	NULL
in	NULL
culture	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
either	NULL
stimulated	NULL
with	NULL
OKT3	NULL
or	NULL
mock-treated	NULL
,	NULL
and	NULL
the	NULL
recombinant	NULL
p85	NULL
constructs	NULL
were	NULL
immunoprecipitated	NULL
from	NULL
Nonidet	NULL
P-40	NULL
lysates	NULL
with	NULL
an	NULL
anti-HA	NULL
antibody	NULL
.	NULL

Recombinant	NULL
proteins	NULL
were	NULL
revealed	NULL
by	NULL
an	NULL
anti-HA	NULL
Western	NULL
blot	NULL
.	NULL

and	NULL
a	NULL
mutated	NULL
form	NULL
of	NULL
p85	NULL
that	NULL
can	NULL
not	NULL
bind	NULL
the	NULL
catalytic	NULL
subunit	NULL
(	NULL
p85AiSH2	NULL
)	NULL
inhibited	NULL
Erk2	NULL
activation	NULL
in	NULL
T	NULL
cells	NULL
(	NULL
22	NULL
)	NULL
.	NULL

To	NULL
further	NULL
investigate	NULL
the	NULL
role	NULL
of	NULL
p85	NULL
domains	NULL
in	NULL
Erk2	NULL
activation	NULL
and	NULL
other	NULL
processes	NULL
relevant	NULL
to	NULL
T	NULL
cell	NULL
activation	NULL
we	NULL
generated	NULL
a	NULL
set	NULL
of	NULL
truncated	NULL
p85	NULL
constructs	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
)	NULL
.	NULL

Transient	NULL
expression	NULL
of	NULL
these	NULL
constructs	NULL
in	NULL
J-TAg	NULL
cells	NULL
yielded	NULL
anti-HA	NULL
reactive	NULL
proteins	NULL
of	NULL
the	NULL
expected	NULL
sizes	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

We	NULL
tested	NULL
these	NULL
constructs	NULL
for	NULL
an	NULL
effect	NULL
on	NULL
Erk2	NULL
activation	NULL
by	NULL
co-expressing	NULL
them	NULL
with	NULL
c-Myc-tagged	NULL
Erk2	NULL
in	NULL
J-TAg	NULL
cells	NULL
.	NULL

48	NULL
h	NULL
after	NULL
transfection	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
either	NULL
stimulated	NULL
for	NULL
3	NULL
min	NULL
with	NULL
the	NULL
anti-CD3	NULL
antibody	NULL
,	NULL
OKT3	NULL
,	NULL
or	NULL
left	NULL
untreated	NULL
.	NULL

c-Myc-tagged	NULL
Erk2	NULL
was	NULL
immunoprecipitated	NULL
using	NULL
the	NULL
mAb	NULL
9E10	NULL
,	NULL
and	NULL
in	NULL
vitro	NULL
kinase	NULL
assays	NULL
were	NULL
performed	NULL
using	NULL
MBP	NULL
as	NULL
a	NULL
substrate	NULL
.	NULL

As	NULL
can	NULL
be	NULL
seen	NULL
in	NULL
the	NULL
upper	NULL
panel	NULL
of	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
only	NULL
p85AiSH2	NULL
clearly	NULL
inhibited	NULL
Erk2	NULL
activation	NULL
,	NULL
presumably	NULL
because	NULL
it	NULL
binds	NULL
to	NULL
PI3-K-activating	NULL
proteins	NULL
or	NULL
sites	NULL
but	NULL
fails	NULL
to	NULL
transduce	NULL
a	NULL
signal	NULL
to	NULL
the	NULL
catalytic	NULL
p110	NULL
subunit	NULL
of	NULL
PI3-K.	NULL
All	NULL
other	NULL
constructs	NULL
had	NULL
negligible	NULL
effects	NULL
on	NULL
Erk2	NULL
activation	NULL
,	NULL
although	NULL
they	NULL
were	NULL
efficiently	NULL
expressed	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
SH3	NULL
domain	NULL
and	NULL
PBP	NULL
seemed	NULL
to	NULL
increase	NULL
Erk2	NULL
activation	NULL
,	NULL
but	NULL
an	NULL
anti-Erk2	NULL
blot	NULL
on	NULL
the	NULL
same	NULL
9E10	NULL
immunoprecipitates	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
lower	NULL
panel	NULL
)	NULL
showed	NULL
that	NULL
these	NULL
two	NULL
samples	NULL
contained	NULL
slightly	NULL
more	NULL
Erk2	NULL
protein	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
seems	NULL
that	NULL
multiple	NULL
domains	NULL
of	NULL
endogenous	NULL
p85	NULL
need	NULL
to	NULL
be	NULL
competed	NULL
away	NULL
by	NULL
transfected	NULL
constructs	NULL
to	NULL
inhibit	NULL
this	NULL
pathway	NULL
.	NULL

610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
/810-0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wo	NULL
;	NULL
popeoumog	NULL
PI3-K	NULL
in	NULL
NFAT	NULL
Activation	NULL
Complex	NULL
Role	NULL
of	NULL
PI3-K	NULL
Domains	NULL
in	NULL
NFAT	NULL
Activation-To	NULL
further	NULL
characterize	NULL
the	NULL
role	NULL
of	NULL
PI3-K	NULL
in	NULL
T	NULL
cell	NULL
activation	NULL
we	NULL
studied	NULL
the	NULL
effect	NULL
of	NULL
truncated	NULL
p85	NULL
and	NULL
p110	NULL
constructs	NULL
on	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
NFAT	NULL
.	NULL

J-TAg	NULL
cells	NULL
were	NULL
co-transfected	NULL
with	NULL
NFAT-lue	NULL
and	NULL
PI3-K	NULL
constructs	NULL
and	NULL
stimulated	NULL
with	NULL
OKT3	NULL
for	NULL
3-4	NULL
h.	NULL
Luciferase	NULL
activity	NULL
was	NULL
assayed	NULL
in	NULL
the	NULL
cell	NULL
lysates	NULL
as	NULL
a	NULL
reporter	NULL
for	NULL
NFAT	NULL
activation	NULL
.	NULL

Fig	NULL
.	NULL

3A	NULL
shows	NULL
that	NULL
PI3-K	NULL
constructs	NULL
had	NULL
complex	NULL
effects	NULL
on	NULL
NFAT	NULL
activity	NULL
following	NULL
TcR/CD3	NULL
stimulation	NULL
.	NULL

The	NULL
SH3	NULL
domain	NULL
,	NULL
a	NULL
fragment	NULL
containing	NULL
two	NULL
proline-rich	NULL
regions	NULL
and	NULL
the	NULL
BCR	NULL
homology	NULL
domain	NULL
(	NULL
PBP	NULL
)	NULL
,	NULL
the	NULL
N-terminal	NULL
SH2	NULL
domain	NULL
(	NULL
N-SH2	NULL
)	NULL
,	NULL
and	NULL
the	NULL
inter-SH2	NULL
domain	NULL
(	NULL
iSH2	NULL
)	NULL
all	NULL
inhibited	NULL
NFAT	NULL
activation	NULL
,	NULL
whereas	NULL
the	NULL
C-terminal	NULL
SH2	NULL
domain	NULL
(	NULL
C-SH2	NULL
)	NULL
increased	NULL
the	NULL
basal	NULL
NFAT	NULL
activity	NULL
without	NULL
affecting	NULL
the	NULL
level	NULL
of	NULL
NFAT	NULL
activity	NULL
after	NULL
TcR/CD3	NULL
stimulation	NULL
.	NULL

The	NULL
C-SH2	NULL
domain	NULL
seemed	NULL
to	NULL
have	NULL
a	NULL
dominant	NULL
effect	NULL
over	NULL
the	NULL
N-SH2	NULL
domain	NULL
since	NULL
constructs	NULL
containing	NULL
both	NULL
SH2	NULL
domains	NULL
(	NULL
p85NC	NULL
and	NULL
p85NiC	NULL
)	NULL
behaved	NULL
more	NULL
like	NULL
C-SH2	NULL
than	NULL
like	NULL
N-SHZ	NULL
.	NULL

p85AiSH2	NULL
and	NULL
full-length	NULL
p85	NULL
both	NULL
lead	NULL
to	NULL
elevated	NULL
basal	NULL
levels	NULL
of	NULL
NFAT	NULL
activity	NULL
with	NULL
almost	NULL
no	NULL
further	NULL
stimulation	NULL
after	NULL
TcR	NULL
engage-ment	NULL
.	NULL

The	NULL
N-terminal	NULL
fragment	NULL
of	NULL
p110	NULL
that	NULL
binds	NULL
p85	NULL
(	NULL
p110	NULL
NT	NULL
)	NULL
did	NULL
not	NULL
substantially	NULL
affect	NULL
NFAT	NULL
activation	NULL
,	NULL
but	NULL
it	NULL
was	NULL
expressed	NULL
at	NULL
a	NULL
lower	NULL
level	NULL
than	NULL
the	NULL
p85	NULL
constructs	NULL
.	NULL

This	NULL
experiment	NULL
was	NULL
repeated	NULL
three	NULL
times	NULL
with	NULL
different	NULL
batches	NULL
of	NULL
DNA	NULL
&	NULL
``	NULL
P	NULL
&	NULL
4	NULL
Po	NULL
5	NULL
I	NULL
Â¢	NULL
â¬	NULL
``	NULL
.	NULL

y	NULL
``	NULL
,	NULL
*	NULL
Â«	NULL
g	NULL
L	NULL
lp	NULL
Boo	NULL
fun	NULL
pty	NULL
G	NULL
Â«	NULL
Â©	NULL
Erk	NULL
?	NULL

L___H	NULL
I	NULL
OKTS	NULL
to	NULL
-	NULL
4	NULL
-	NULL
+	NULL
+	NULL
+o	NULL
o-	NULL
+	NULL
+o	NULL
-	NULL
+	NULL
we	NULL
|	NULL
-	NULL
MBP	NULL
Erk2	NULL
assay	NULL
%	NULL
.	NULL
'	NULL

*	NULL
*	NULL
*=	NULL
Erk2	NULL
blot	NULL
apeb	NULL
Â«	NULL
reas	NULL
|	NULL
.	NULL

-	NULL
L2	NULL
=	NULL
wns	NULL
ae	NULL
das	NULL
our	NULL
dah	NULL
wut	NULL
ame	NULL
wie	NULL
dite	NULL
Fic	NULL
.	NULL

2	NULL
.	NULL

Effects	NULL
of	NULL
p85	NULL
constructs	NULL
on	NULL
Erk2	NULL
activation	NULL
.	NULL

In	NULL
vitro	NULL
kinase	NULL
assay	NULL
(	NULL
top	NULL
)	NULL
using	NULL
myelin	NULL
basic	NULL
protein	NULL
(	NULL
MBP	NULL
)	NULL
as	NULL
a	NULL
substrate	NULL
of	NULL
immunoprecipitates	NULL
obtained	NULL
with	NULL
the	NULL
anti-tag	NULL
mAb	NULL
9610	NULL
from	NULL
J-Tag	NULL
cells	NULL
transiently	NULL
cotransfected	NULL
with	NULL
vector	NULL
alone	NULL
(	NULL
20	NULL
ug	NULL
)	NULL
or	NULL
tagged	NULL
Erk2	NULL
(	NULL
5	NULL
ug	NULL
)	NULL
plus	NULL
vector	NULL
or	NULL
the	NULL
indicated	NULL
p85	NULL
constructs	NULL
(	NULL
15	NULL
ug	NULL
)	NULL
.	NULL

Bofftom	NULL
,	NULL
anti-Erk2	NULL
blot	NULL
of	NULL
the	NULL
same	NULL
immunoprecipitates	NULL
.	NULL

A	NULL
14485	NULL
and	NULL
yielded	NULL
very	NULL
reproducible	NULL
results	NULL
.	NULL

Activation	NULL
of	NULL
NFAT	NULL
requires	NULL
two	NULL
signals	NULL
,	NULL
one	NULL
involving	NULL
calcium	NULL
(	NULL
inducible	NULL
by	NULL
ionomycin	NULL
)	NULL
,	NULL
and	NULL
one	NULL
involving	NULL
Ras	NULL
(	NULL
inducible	NULL
by	NULL
PMA	NULL
,	NULL
;	NULL
reviewed	NULL
in	NULL
Ref	NULL
.	NULL

25	NULL
)	NULL
.	NULL

To	NULL
test	NULL
whether	NULL
the	NULL
mutated	NULL
PI3-K	NULL
constructs	NULL
used	NULL
in	NULL
this	NULL
study	NULL
acted	NULL
in	NULL
the	NULL
calcium	NULL
pathway	NULL
or	NULL
in	NULL
the	NULL
Ras	NULL
pathway	NULL
,	NULL
we	NULL
tested	NULL
their	NULL
effect	NULL
on	NULL
NFAT	NULL
activation	NULL
in	NULL
cells	NULL
that	NULL
had	NULL
been	NULL
stimulated	NULL
with	NULL
either	NULL
PMA	NULL
or	NULL
ionomycin	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

PMA	NULL
alone	NULL
did	NULL
not	NULL
activate	NULL
NFAT	NULL
,	NULL
and	NULL
none	NULL
of	NULL
the	NULL
p85	NULL
mutants	NULL
had	NULL
a	NULL
synergistic	NULL
effect	NULL
on	NULL
NFAT	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
PMA	NULL
.	NULL

Ionomycin	NULL
,	NULL
on	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
synergis-tically	NULL
activated	NULL
NFAT	NULL
in	NULL
cells	NULL
that	NULL
were	NULL
transfected	NULL
with	NULL
p85	NULL
constructs	NULL
containing	NULL
the	NULL
C-terminal	NULL
SH2	NULL
domain	NULL
.	NULL

We	NULL
conclude	NULL
that	NULL
these	NULL
``	NULL
activating	NULL
``	NULL
mutants	NULL
mimicked	NULL
or	NULL
induced	NULL
a	NULL
process	NULL
in	NULL
the	NULL
Ras/PKC	NULL
pathway	NULL
,	NULL
which	NULL
together	NULL
with	NULL
an	NULL
increase	NULL
in	NULL
intracellular	NULL
calcium	NULL
lead	NULL
to	NULL
a	NULL
strong	NULL
activation	NULL
of	NULL
NFAT	NULL
.	NULL

Cyclosporin	NULL
A	NULL
Inhibits	NULL
TcR-induced	NULL
and	NULL
p8S5NC-induced	NULL
NFAT	NULL
Activation-Calcineurin	NULL
is	NULL
a	NULL
cytosolic	NULL
Ser/Thr-specific	NULL
protein	NULL
phosphatase	NULL
that	NULL
dephosphorylates	NULL
NFATp	NULL
in	NULL
a	NULL
calci-um/calmodulin-dependent	NULL
way	NULL
,	NULL
a	NULL
critical	NULL
step	NULL
for	NULL
nuclear	NULL
translocation	NULL
of	NULL
NFATp	NULL
and	NULL
assembly	NULL
of	NULL
functional	NULL
NFAT	NULL
com-plexes	NULL
.	NULL

To	NULL
ask	NULL
if	NULL
calcineurin	NULL
is	NULL
involved	NULL
in	NULL
NFAT	NULL
activation	NULL
by	NULL
p85NC	NULL
,	NULL
we	NULL
took	NULL
advantage	NULL
of	NULL
the	NULL
immunosuppressant	NULL
,	NULL
cyclosporin	NULL
A	NULL
(	NULL
CsA	NULL
)	NULL
,	NULL
a	NULL
potent	NULL
inhibitor	NULL
of	NULL
calcineurin	NULL
(	NULL
26	NULL
,	NULL
27	NULL
)	NULL
.	NULL

Fig	NULL
.	NULL

4	NULL
shows	NULL
that	NULL
CsA	NULL
efficiently	NULL
inhibited	NULL
NFAT	NULL
activation	NULL
after	NULL
stimulation	NULL
with	NULL
either	NULL
OKT3	NULL
or	NULL
ionomycin	NULL
.	NULL

In	NULL
cells	NULL
transfected	NULL
with	NULL
inhibitory	NULL
p85	NULL
constructs	NULL
(	NULL
SH8	NULL
,	NULL
PBP	NULL
,	NULL
and	NULL
N-SH2	NULL
)	NULL
,	NULL
CsA	NULL
inhibited	NULL
NFAT	NULL
even	NULL
further	NULL
.	NULL

Because	NULL
the	NULL
inhibition	NULL
of	NULL
NFAT	NULL
that	NULL
is	NULL
caused	NULL
by	NULL
these	NULL
p85	NULL
constructs	NULL
seems	NULL
to	NULL
have	NULL
an	NULL
additional	NULL
effect	NULL
to	NULL
the	NULL
inhibition	NULL
mediated	NULL
by	NULL
CsA	NULL
,	NULL
we	NULL
speculate	NULL
that	NULL
also	NULL
these	NULL
p85	NULL
constructs	NULL
act	NULL
in	NULL
the	NULL
Ras/PKC	NULL
pathway	NULL
.	NULL

In	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
activating	NULL
construct	NULL
,	NULL
p85NC	NULL
,	NULL
inhibition	NULL
by	NULL
CsA	NULL
was	NULL
substantial	NULL
,	NULL
but	NULL
not	NULL
complete	NULL
.	NULL

This	NULL
is	NULL
compatible	NULL
with	NULL
pS5NC	NULL
stimulating	NULL
the	NULL
Ras/PKC-dependent	NULL
pathway	NULL
.	NULL

Dominant	NULL
Negative	NULL
Ras	NULL
Blocks	NULL
NFAT	NULL
Activation	NULL
by	NULL
pSSNC-The	NULL
Ras	NULL
GTPase	NULL
has	NULL
been	NULL
implicated	NULL
in	NULL
PI3-K	NULL
signaling	NULL
(	NULL
28	NULL
)	NULL
and	NULL
has	NULL
been	NULL
demonstrated	NULL
to	NULL
bind	NULL
directly	NULL
to	NULL
the	NULL
catalytic	NULL
subunit	NULL
of	NULL
PI3-K	NULL
(	NULL
21	NULL
)	NULL
.	NULL

To	NULL
address	NULL
whether	NULL
the	NULL
increase	NULL
in	NULL
basal	NULL
NFAT	NULL
activity	NULL
in	NULL
cells	NULL
expressing	NULL
p8SSNC	NULL
requires	NULL
functional	NULL
Ras	NULL
,	NULL
we	NULL
co-transfected	NULL
cells	NULL
with	NULL
NFAT-luc	NULL
,	NULL
p85SNC	NULL
,	NULL
and	NULL
increasing	NULL
amounts	NULL
of	NULL
dominant	NULL
negative	NULL
Ras	NULL
(	NULL
RasN17	NULL
)	NULL
.	NULL

Both	NULL
the	NULL
basal	NULL
NFAT	NULL
activity	NULL
in	NULL
unstimulated	NULL
cells	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
TcR-induced	NULL
activation	NULL
,	NULL
were	NULL
inhibited	NULL
by	NULL
RasN17	NULL
in	NULL
a	NULL
dose-de-pendent	NULL
manner	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

It	NULL
is	NULL
important	NULL
to	NULL
note	NULL
that	NULL
the	NULL
ex	NULL
B	NULL
Fic	NULL
.	NULL

3	NULL
.	NULL

Involvement	NULL
of	NULL
PI3-K	NULL
in	NULL
NFAT	NULL
activation	NULL
.	NULL

J-TAg	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
either	NULL
empty	NULL
vector	NULL
(	NULL
17	NULL
ug	NULL
)	NULL
or	NULL
NFAT-luc	NULL
(	NULL
2	NULL
pg	NULL
)	NULL
plus	NULL
empty	NULL
vector	NULL
(	NULL
15	NULL
ug	NULL
)	NULL
or	NULL
NFAT-lue	NULL
(	NULL
2	NULL
ug	NULL
)	NULL
plus	NULL
recombinant	NULL
PI8-K	NULL
constructs	NULL
(	NULL
15	NULL
ug	NULL
)	NULL
.	NULL

Two	NULL
days	NULL
later	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
either	NULL
mock-treated	NULL
,	NULL
or	NULL
stimulated	NULL
with	NULL
OKT3	NULL
,	NULL
PMA	NULL
,	NULL
ionomycin	NULL
,	NULL
or	NULL
PMA	NULL
plus	NULL
ionomycin	NULL
for	NULL
3	NULL
h	NULL
,	NULL
and	NULL
cell	NULL
lysates	NULL
were	NULL
assayed	NULL
for	NULL
luciferase	NULL
activity	NULL
and	NULL
for	NULL
protein	NULL
concentration	NULL
.	NULL

Luminescence	NULL
units	NULL
were	NULL
corrected	NULL
for	NULL
protein	NULL
concentration	NULL
in	NULL
the	NULL
ly-sates	NULL
,	NULL
and	NULL
the	NULL
data	NULL
are	NULL
presented	NULL
as	NULL
percent	NULL
of	NULL
maximal	NULL
activation	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
activation	NULL
by	NULL
PMA	NULL
plus	NULL
ionomycin	NULL
.	NULL

The	NULL
two	NULL
panels	NULL
are	NULL
from	NULL
the	NULL
same	NULL
%	NULL
of	NULL
maximal	NULL
activation	NULL
PMA	NULL
ionomycin	NULL
experiment	NULL
and	NULL
are	NULL
only	NULL
separated	NULL
for	NULL
easier	NULL
viewing	NULL
.	NULL

5	NULL
5	NULL
s	NULL
&	NULL
a	NULL
wo	NULL
2	NULL
EP	NULL
M	NULL
I	NULL
$	NULL
op	NULL
5	NULL
c	NULL
I	NULL
>	NULL
>	NULL
Z	NULL
NFAT	NULL
Â«	NULL
o	NULL
g	NULL
a	NULL
a	NULL
n	NULL
E	NULL
5	NULL
6	NULL
s	NULL
&	NULL
<	NULL
N	NULL
o	NULL
g	NULL
a	NULL
8	NULL
ou	NULL
E	NULL
I	NULL
>	NULL
I	NULL
I	NULL
Z	NULL
5	NULL
M	NULL
E	NULL
E	NULL
3	NULL
I	NULL
E	NULL
3	NULL
a	NULL
7T	NULL
Z	NULL
Â»	NULL
5	NULL
%	NULL
1	NULL
b	NULL
t	NULL
a	NULL
a	NULL
a	NULL
a	NULL
``	NULL
Z	NULL
m	NULL
a	NULL
2	NULL
)	NULL
3	NULL
4	NULL
0	NULL
o	NULL
304	NULL
O	NULL
in	NULL
:	NULL
>	NULL
>	NULL
2	NULL
O	NULL
g	NULL
L-	NULL
Â«	NULL
o	NULL
sa	NULL
o	NULL
a	NULL
a	NULL
.	NULL

610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
/810-0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wo	NULL
;	NULL
popeoumog	NULL
14486	NULL
120000	NULL
100000	NULL
B0000	NULL
M	NULL
resting	NULL
H	NULL
OKT3	NULL
E	NULL
ionomycin	NULL
60000	NULL
40000	NULL
1	NULL
luciferase	NULL
activity	NULL
20000	NULL
CsA	NULL
csal	NULL
__	NULL
|osa|	NULL
__	NULL
[	NULL
osa	NULL
CeA	NULL
SH3	NULL
PEP	NULL
N-SH2	NULL
NC	NULL
6000	NULL
7	NULL
4000	NULL
2000	NULL
0	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

NFAT	NULL
activation	NULL
requires	NULL
calcineurin	NULL
.	NULL

J-TAg	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
NFAT-lue	NULL
(	NULL
2	NULL
pg	NULL
)	NULL
plus	NULL
empty	NULL
vector	NULL
or	NULL
recombinant	NULL
p85	NULL
constructs	NULL
(	NULL
15	NULL
ug	NULL
)	NULL
.	NULL

Two	NULL
days	NULL
later	NULL
the	NULL
cells	NULL
were	NULL
pretreated	NULL
with	NULL
100	NULL
nM	NULL
cyclosporin	NULL
A	NULL
or	NULL
mock-treated	NULL
for	NULL
15	NULL
min	NULL
,	NULL
followed	NULL
by	NULL
stimulation	NULL
with	NULL
control	NULL
medium	NULL
or	NULL
OKT3	NULL
or	NULL
ionomycin	NULL
for	NULL
3	NULL
h.	NULL
Cell	NULL
lysates	NULL
were	NULL
assayed	NULL
for	NULL
luciferase	NULL
activity	NULL
and	NULL
protein	NULL
concentration	NULL
.	NULL

The	NULL
data	NULL
are	NULL
presented	NULL
as	NULL
arbitrary	NULL
luminescence	NULL
units	NULL
corrected	NULL
for	NULL
protein	NULL
concentration	NULL
,	NULL
and	NULL
the	NULL
lower	NULL
panel	NULL
represents	NULL
a	NULL
magnified	NULL
view	NULL
of	NULL
the	NULL
lower	NULL
part	NULL
of	NULL
the	NULL
upper	NULL
panel	NULL
(	NULL
note	NULL
the	NULL
scale	NULL
)	NULL
.	NULL

pression	NULL
level	NULL
of	NULL
p85NC	NULL
was	NULL
not	NULL
affected	NULL
by	NULL
RasN17	NULL
.	NULL

Therefore	NULL
,	NULL
RasN17-mediated	NULL
abrogation	NULL
of	NULL
p85NC-induced	NULL
basal	NULL
NFAT	NULL
activity	NULL
can	NULL
not	NULL
be	NULL
explained	NULL
by	NULL
loss	NULL
of	NULL
p8SNC	NULL
expression	NULL
.	NULL

Wortmannin	NULL
Does	NULL
Not	NULL
Inhibit	NULL
NFAT	NULL
Activation-To	NULL
understand	NULL
the	NULL
complex	NULL
effects	NULL
on	NULL
NFAT	NULL
activation	NULL
of	NULL
the	NULL
mutant	NULL
p85	NULL
constructs	NULL
used	NULL
in	NULL
this	NULL
study	NULL
,	NULL
we	NULL
sought	NULL
to	NULL
correlate	NULL
them	NULL
with	NULL
the	NULL
catalytic	NULL
activity	NULL
of	NULL
endogenous	NULL
PI3-K	NULL
in	NULL
the	NULL
transfected	NULL
cells	NULL
.	NULL

We	NULL
therefore	NULL
decided	NULL
to	NULL
ask	NULL
first	NULL
whether	NULL
PI3-K	NULL
catalytic	NULL
activity	NULL
is	NULL
required	NULL
for	NULL
NFAT	NULL
activation	NULL
.	NULL

Wortmannin	NULL
has	NULL
been	NULL
widely	NULL
used	NULL
to	NULL
irreversibly	NULL
inhibit	NULL
PI3-K	NULL
and	NULL
to	NULL
demonstrate	NULL
the	NULL
involvement	NULL
of	NULL
PI3-K	NULL
in	NULL
many	NULL
cellular	NULL
processes	NULL
(	NULL
29	NULL
)	NULL
.	NULL

We	NULL
transiently	NULL
transfected	NULL
cells	NULL
with	NULL
NFAT-lue	NULL
(	NULL
plus	NULL
empty	NULL
vector	NULL
)	NULL
.	NULL

Two	NULL
days	NULL
after	NULL
transfection	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
increasing	NULL
concentrations	NULL
of	NULL
wortmannin	NULL
for	NULL
30	NULL
min	NULL
and	NULL
then	NULL
stimulated	NULL
with	NULL
OKT3	NULL
for	NULL
3	NULL
h.	NULL
To	NULL
verify	NULL
inhibition	NULL
of	NULL
PI3-K	NULL
by	NULL
wortmannin	NULL
,	NULL
samples	NULL
were	NULL
taken	NULL
at	NULL
the	NULL
beginning	NULL
and	NULL
at	NULL
the	NULL
end	NULL
of	NULL
the	NULL
OKT3-stimulation	NULL
(	NULL
after	NULL
3	NULL
min	NULL
and	NULL
3	NULL
h	NULL
,	NULL
respectively	NULL
)	NULL
and	NULL
from	NULL
unstimulated	NULL
control	NULL
cells	NULL
and	NULL
assayed	NULL
for	NULL
PI3-K	NULL
activity	NULL
in	NULL
p85	NULL
immunoprecipitates	NULL
.	NULL

Activation	NULL
of	NULL
Erk2	NULL
was	NULL
tested	NULL
by	NULL
immunoblotting	NULL
of	NULL
total	NULL
cell	NULL
lysates	NULL
of	NULL
the	NULL
same	NULL
samples	NULL
with	NULL
an	NULL
anti-phospho-Erk2	NULL
antibody	NULL
.	NULL

After	NULL
3	NULL
h	NULL
of	NULL
stimulation	NULL
with	NULL
OKT3	NULL
,	NULL
cell	NULL
lysates	NULL
were	NULL
prepared	NULL
and	NULL
assayed	NULL
for	NULL
luciferase	NULL
activity	NULL
.	NULL

The	NULL
upper	NULL
panel	NULL
of	NULL
Fig	NULL
.	NULL

6	NULL
shows	NULL
that	NULL
increasing	NULL
concentrations	NULL
of	NULL
wortmannin	NULL
progressively	NULL
inhibited	NULL
PI3-K	NULL
activity	NULL
,	NULL
and	NULL
that	NULL
this	NULL
inhibition	NULL
lasted	NULL
for	NULL
the	NULL
entire	NULL
duration	NULL
of	NULL
the	NULL
stimulation	NULL
with	NULL
OKT3	NULL
.	NULL

This	NULL
is	NULL
impor-tant	NULL
,	NULL
because	NULL
wortmannin	NULL
is	NULL
known	NULL
to	NULL
be	NULL
unstable	NULL
,	NULL
and	NULL
de	NULL
novo	NULL
synthesis	NULL
of	NULL
PI3-K	NULL
might	NULL
partially	NULL
reverse	NULL
the	NULL
effect	NULL
of	NULL
wortmannin	NULL
once	NULL
it	NULL
is	NULL
hydrolyzed	NULL
.	NULL

Erk2	NULL
activation	NULL
was	NULL
observed	NULL
after	NULL
3	NULL
min	NULL
of	NULL
stimulation	NULL
and	NULL
was	NULL
sensitive	NULL
to	NULL
wortmannin	NULL
as	NULL
shown	NULL
before	NULL
(	NULL
22	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
middle	NULL
)	NULL
.	NULL

No	NULL
Erk2	NULL
activation	NULL
was	NULL
observed	NULL
after	NULL
3	NULL
h	NULL
of	NULL
stimulation	NULL
with	NULL
OKT3	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Surprisingly	NULL
,	NULL
wortmannin	NULL
did	NULL
not	NULL
inhibit	NULL
NFAT	NULL
activation	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
lower	NULL
panel	NULL
)	NULL
.	NULL

At	NULL
the	NULL
highest	NULL
wortmannin	NULL
concentration	NULL
,	NULL
we	NULL
tested	NULL
to	NULL
achieve	NULL
complete	NULL
inhibition	NULL
of	NULL
PI3-K	NULL
,	NULL
NFAT	NULL
activation	NULL
was	NULL
even	NULL
higher	NULL
than	NULL
in	NULL
untreated	NULL
cells	NULL
,	NULL
but	NULL
this	NULL
may	NULL
be	NULL
due	NULL
to	NULL
lack	NULL
of	NULL
specificity	NULL
of	NULL
wortmannin	NULL
at	NULL
this	NULL
concentration	NULL
.	NULL

PI3-K	NULL
in	NULL
NFAT	NULL
Activation	NULL
80	NULL
E	NULL
E	NULL
-	NULL
resting	NULL
Â§	NULL
Ba	NULL
OKT3	NULL
t	NULL
Â®	NULL
Â£	NULL
%	NULL
fel	NULL
E	NULL
6	NULL
0	NULL
&	NULL
NFAT	NULL
+	NULL
NC9	NULL
ug	NULL
mo	NULL
e	NULL
+	NULL
poe	NULL
o	NULL
>	NULL
Bos	NULL
0	NULL
c	NULL
od	NULL
oc	NULL
c	NULL
4	NULL
&	NULL
0	NULL
~	NULL
c	NULL
+	NULL
>	NULL
OKT3	NULL
nop	NULL
>	NULL
>	NULL
o	NULL
>	NULL
>	NULL
#	NULL
00	NULL
>	NULL
>	NULL
o-	NULL
>	NULL
40	NULL
>	NULL
+	NULL
+	NULL
PMA	NULL
+	NULL
ionomycin	NULL
was	NULL
cae	NULL
GP	NULL
cam	NULL
cae	NULL
Cit	NULL
aam	NULL
cas	NULL
C	NULL
.	NULL

--	NULL
NC	NULL
IHasdpg|Rasng	NULL
|FÂ¥as4ug1m59ug	NULL
NFAT	NULL
NFAT	NULL
+	NULL
NC	NULL
Fic	NULL
.	NULL

5	NULL
.	NULL

NFAT	NULL
activation	NULL
by	NULL
pS5SNC	NULL
requires	NULL
functional	NULL
Ras	NULL
.	NULL

J-TAg	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
NFAT-luc	NULL
(	NULL
2	NULL
ug	NULL
)	NULL
plus	NULL
the	NULL
indicated	NULL
constructs	NULL
and	NULL
empty	NULL
vector	NULL
to	NULL
give	NULL
a	NULL
total	NULL
amount	NULL
of	NULL
DNA	NULL
of	NULL
20	NULL
ug	NULL
for	NULL
each	NULL
transfection	NULL
.	NULL

After	NULL
2	NULL
days	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
stimulated	NULL
either	NULL
with	NULL
control	NULL
medium	NULL
or	NULL
with	NULL
OKT3	NULL
or	NULL
with	NULL
PMA	NULL
plus	NULL
ionomycin	NULL
for	NULL
3	NULL
h	NULL
,	NULL
and	NULL
cell	NULL
lysates	NULL
were	NULL
assayed	NULL
for	NULL
luciferase	NULL
(	NULL
fop	NULL
panel	NULL
)	NULL
.	NULL

Lysate	NULL
samples	NULL
were	NULL
subjected	NULL
to	NULL
an	NULL
anti-HA	NULL
Western	NULL
blot	NULL
to	NULL
control	NULL
for	NULL
NC	NULL
expression	NULL
levels	NULL
(	NULL
bottom	NULL
panels	NULL
)	NULL
.	NULL

The	NULL
three	NULL
lanes	NULL
shown	NULL
for	NULL
each	NULL
transfection	NULL
are	NULL
from	NULL
cells	NULL
that	NULL
were	NULL
either	NULL
untreated	NULL
or	NULL
stimulated	NULL
with	NULL
OKT3	NULL
or	NULL
with	NULL
PMA	NULL
plus	NULL
ionomycin	NULL
.	NULL

We	NULL
therefore	NULL
conclude	NULL
that	NULL
the	NULL
kinase	NULL
activity	NULL
of	NULL
PI3-K	NULL
is	NULL
not	NULL
required	NULL
for	NULL
NFAT	NULL
activation	NULL
or	NULL
may	NULL
even	NULL
have	NULL
an	NULL
inhibitory	NULL
effect	NULL
.	NULL

Cellular	NULL
Protein	NULL
Binding	NULL
to	NULL
PI3K	NULL
Domains-The	NULL
effect	NULL
of	NULL
p85	NULL
domains	NULL
on	NULL
NFAT	NULL
is	NULL
likely	NULL
to	NULL
be	NULL
mediated	NULL
by	NULL
cellular	NULL
proteins	NULL
that	NULL
bind	NULL
to	NULL
them	NULL
.	NULL

To	NULL
learn	NULL
more	NULL
about	NULL
the	NULL
role	NULL
of	NULL
PI3-K	NULL
domains	NULL
in	NULL
NFAT	NULL
activation	NULL
,	NULL
we	NULL
transiently	NULL
expressed	NULL
the	NULL
constructs	NULL
described	NULL
above	NULL
in	NULL
J-TAg	NULL
cells	NULL
and	NULL
immunoprecipitated	NULL
them	NULL
with	NULL
an	NULL
anti-HA	NULL
antibody	NULL
from	NULL
resting	NULL
and	NULL
from	NULL
OKT3-stimulated	NULL
cells	NULL
.	NULL

Bound	NULL
phosphotyrosine-containing	NULL
proteins	NULL
were	NULL
revealed	NULL
by	NULL
anti-phosphotyrosine	NULL
Western	NULL
blotting	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

While	NULL
the	NULL
SH3	NULL
domain	NULL
and	NULL
the	NULL
PBP	NULL
fragment	NULL
did	NULL
not	NULL
associate	NULL
with	NULL
phosphotyrosine-containing	NULL
proteins	NULL
,	NULL
all	NULL
constructs	NULL
that	NULL
contained	NULL
one	NULL
or	NULL
two	NULL
SH2	NULL
domains	NULL
coprecipi-tated	NULL
with	NULL
a	NULL
similar	NULL
set	NULL
of	NULL
proteins	NULL
.	NULL

A	NULL
tandem	NULL
arrangement	NULL
of	NULL
the	NULL
two	NULL
SH2	NULL
domains	NULL
seemed	NULL
to	NULL
be	NULL
essential	NULL
for	NULL
efficient	NULL
binding	NULL
to	NULL
cellular	NULL
phosphotyrosine-containing	NULL
proteins	NULL
,	NULL
especially	NULL
for	NULL
the	NULL
~21-kDa	NULL
protein	NULL
,	NULL
which	NULL
we	NULL
identified	NULL
as	NULL
the	NULL
TeR	NULL
Â£	NULL
chain	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

However	NULL
,	NULL
there	NULL
was	NULL
no	NULL
major	NULL
difference	NULL
in	NULL
the	NULL
pattern	NULL
of	NULL
proteins	NULL
bound	NULL
to	NULL
either	NULL
the	NULL
N-SH2	NULL
domain	NULL
or	NULL
the	NULL
C-SH2	NULL
domain	NULL
.	NULL

The	NULL
functional	NULL
difference	NULL
of	NULL
the	NULL
two	NULL
SH2	NULL
domain	NULL
constructs	NULL
with	NULL
regard	NULL
to	NULL
NFAT	NULL
stimulation	NULL
can	NULL
therefore	NULL
not	NULL
readily	NULL
be	NULL
explained	NULL
by	NULL
different	NULL
binding	NULL
characteristics	NULL
of	NULL
the	NULL
SH2	NULL
domains	NULL
.	NULL

DISCUSSION	NULL
In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
overexpressed	NULL
potentially	NULL
dominant	NULL
negative	NULL
mutants	NULL
to	NULL
investigate	NULL
the	NULL
role	NULL
of	NULL
heterodimeric	NULL
p85/p110	NULL
PI3-K	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
mitogen-activated	NULL
kinase	NULL
,	NULL
Erk2	NULL
,	NULL
and	NULL
the	NULL
transcription	NULL
factor	NULL
,	NULL
NFAT	NULL
.	NULL

We	NULL
found	NULL
that	NULL
PI3-K	NULL
was	NULL
involved	NULL
in	NULL
both	NULL
processes	NULL
,	NULL
but	NULL
in	NULL
fundamentally	NULL
different	NULL
ways	NULL
.	NULL

Erk2	NULL
activation	NULL
was	NULL
inhibited	NULL
by	NULL
wortmannin	NULL
and	NULL
by	NULL
a	NULL
mutated	NULL
p85	NULL
that	NULL
can	NULL
not	NULL
bind	NULL
to	NULL
the	NULL
catalytic	NULL
p110	NULL
subunit	NULL
,	NULL
but	NULL
overexpression	NULL
of	NULL
other	NULL
p85	NULL
constructs	NULL
had	NULL
no	NULL
effect	NULL
.	NULL

Activation	NULL
of	NULL
NFAT	NULL
,	NULL
on	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
was	NULL
insensitive	NULL
to	NULL
wortmannin	NULL
,	NULL
but	NULL
was	NULL
affected	NULL
by	NULL
overexpression	NULL
of	NULL
truncated	NULL
forms	NULL
of	NULL
p85	NULL
in	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
/810-0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wo	NULL
;	NULL
popeoumog	NULL
PI3-K	NULL
in	NULL
NFAT	NULL
Activation	NULL
Fic	NULL
.	NULL

6	NULL
.	NULL

PI3S-K	NULL
activity	NULL
is	NULL
not	NULL
required	NULL
for	NULL
NFAT	NULL
activation	NULL
.	NULL

J-TAg	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
2	NULL
ug	NULL
NFAT-lue	NULL
plus	NULL
15	NULL
ug	NULL
of	NULL
empty	NULL
vector	NULL
.	NULL

After	NULL
2	NULL
days	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
washed	NULL
four	NULL
times	NULL
with	NULL
serum-free	NULL
medium	NULL
,	NULL
and	NULL
treated	NULL
with	NULL
the	NULL
indicated	NULL
concentrations	NULL
of	NULL
wortmannin	NULL
for	NULL
30	NULL
min	NULL
at	NULL
87Â°C	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
stimulated	NULL
with	NULL
OKT3	NULL
or	NULL
control	NULL
me-dium	NULL
.	NULL

After	NULL
3	NULL
min	NULL
and	NULL
again	NULL
after	NULL
3	NULL
h	NULL
of	NULL
stimulation	NULL
,	NULL
samples	NULL
were	NULL
taken	NULL
and	NULL
the	NULL
endogenous	NULL
PIS8-K	NULL
was	NULL
immunoprecipitated	NULL
from	NULL
lysates	NULL
and	NULL
subjected	NULL
to	NULL
in	NULL
vitro	NULL
lipid	NULL
kinase	NULL
assays	NULL
using	NULL
phosphatidylinositol	NULL
and	NULL
[	NULL
y-*	NULL
``	NULL
P	NULL
]	NULL
ATP	NULL
as	NULL
substrates	NULL
to	NULL
verify	NULL
inhibition	NULL
of	NULL
PI3-K	NULL
by	NULL
wortmannin	NULL
(	NULL
fop	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
Erk2	NULL
was	NULL
tested	NULL
by	NULL
Western	NULL
blotting	NULL
with	NULL
an	NULL
anti-phospho-Erk2	NULL
antibody	NULL
on	NULL
cell	NULL
lysates	NULL
from	NULL
the	NULL
3-min	NULL
time	NULL
point	NULL
(	NULL
left	NULL
bottom	NULL
panel	NULL
)	NULL
,	NULL
and	NULL
NFAT	NULL
activation	NULL
measured	NULL
by	NULL
luciferase	NULL
assays	NULL
from	NULL
the	NULL
3-h	NULL
points	NULL
(	NULL
right	NULL
bottom	NULL
panel	NULL
)	NULL
.	NULL

Fig	NULL
.	NULL

7	NULL
.	NULL

Cellular	NULL
phosphotyrosine-containing	NULL
proteins	NULL
associated	NULL
with	NULL
recombinant	NULL
p85	NULL
constructs	NULL
.	NULL

The	NULL
nitrocellulose	NULL
filter	NULL
used	NULL
in	NULL
Fig	NULL
.	NULL

1B	NULL
was	NULL
stripped	NULL
and	NULL
re-probed	NULL
with	NULL
anti-phosphotyrosine	NULL
antibody	NULL
.	NULL

The	NULL
bands	NULL
at	NULL
55	NULL
and	NULL
25	NULL
kDa	NULL
are	NULL
the	NULL
heavy	NULL
and	NULL
light	NULL
chains	NULL
,	NULL
respectively	NULL
,	NULL
of	NULL
the	NULL
anti-HA	NULL
antibody	NULL
used	NULL
for	NULL
the	NULL
immunoprecipitation	NULL
.	NULL

a	NULL
different	NULL
way	NULL
than	NULL
Erk2	NULL
.	NULL

To	NULL
the	NULL
best	NULL
of	NULL
our	NULL
knowledge	NULL
,	NULL
this	NULL
is	NULL
the	NULL
first	NULL
report	NULL
that	NULL
describes	NULL
a	NULL
role	NULL
of	NULL
PI3-K	NULL
in	NULL
NFAT	NULL
activation	NULL
.	NULL

Since	NULL
catalytic	NULL
activity	NULL
does	NULL
not	NULL
seem	NULL
to	NULL
be	NULL
involved	NULL
,	NULL
we	NULL
speculate	NULL
that	NULL
p85	NULL
may	NULL
have	NULL
an	NULL
adaptor	NULL
function	NULL
that	NULL
is	NULL
crucial	NULL
for	NULL
NFAT	NULL
activation	NULL
.	NULL

This	NULL
adaptor	NULL
function	NULL
would	NULL
not	NULL
only	NULL
recruit	NULL
p110	NULL
to	NULL
the	NULL
membrane	NULL
but	NULL
also	NULL
bring	NULL
other	NULL
signaling	NULL
proteins	NULL
together	NULL
,	NULL
which	NULL
then	NULL
activate	NULL
NFAT	NULL
.	NULL

The	NULL
used	NULL
p85	NULL
constructs	NULL
fall	NULL
into	NULL
two	NULL
classes	NULL
:	NULL
(	NULL
i	NULL
)	NULL
those	NULL
that	NULL
inhibit	NULL
TeR/CD3-mediated	NULL
NFAT	NULL
activation	NULL
(	NULL
SH3	NULL
,	NULL
PBP	NULL
,	NULL
N-SH2	NULL
,	NULL
and	NULL
iSH2	NULL
)	NULL
and	NULL
(	NULL
ii	NULL
)	NULL
those	NULL
that	NULL
increase	NULL
NFAT	NULL
activity	NULL
in	NULL
resting	NULL
cells	NULL
and	NULL
synergize	NULL
with	NULL
ionomycin	NULL
(	NULL
C-SH2	NULL
,	NULL
NC	NULL
,	NULL
NiC	NULL
,	NULL
p85AiSH2	NULL
,	NULL
wild-type	NULL
p85	NULL
)	NULL
.	NULL

Most	NULL
striking	NULL
is	NULL
perhaps	NULL
that	NULL
the	NULL
two	NULL
SH2	NULL
domains	NULL
had	NULL
opposite	NULL
effects	NULL
on	NULL
NFAT	NULL
activation	NULL
although	NULL
their	NULL
sequence	NULL
specificity	NULL
for	NULL
phosphoprotein	NULL
binding	NULL
is	NULL
similar	NULL
(	NULL
Y*XXM	NULL
)	NULL
(	NULL
30	NULL
)	NULL
,	NULL
and	NULL
although	NULL
they	NULL
bound	NULL
a	NULL
comparable	NULL
pattern	NULL
of	NULL
cellular	NULL
phosphotyrosine-containing	NULL
proteins	NULL
.	NULL

It	NULL
is	NULL
interesting	NULL
to	NULL
note	NULL
that	NULL
in	NULL
a	NULL
study	NULL
using	NULL
microinjected	NULL
antibodies	NULL
against	NULL
either	NULL
SH2	NULL
domain	NULL
of	NULL
p85	NULL
,	NULL
anti-N-SH2	NULL
antibodies	NULL
had	NULL
a	NULL
different	NULL
effect	NULL
than	NULL
anti-C-SH2	NULL
antibodies	NULL
(	NULL
31	NULL
)	NULL
.	NULL

We	NULL
have	NULL
attempted	NULL
to	NULL
identify	NULL
proteins	NULL
that	NULL
bind	NULL
to	NULL
the	NULL
p85	NULL
mutants	NULL
used	NULL
here	NULL
in	NULL
a	NULL
way	NULL
that	NULL
would	NULL
explain	NULL
their	NULL
role	NULL
in	NULL
NFAT	NULL
activation	NULL
,	NULL
but	NULL
Western	NULL
blotting	NULL
using	NULL
antibodies	NULL
against	NULL
c-Cbl	NULL
(	NULL
32	NULL
,	NULL
33	NULL
)	NULL
,	NULL
Grb2	NULL
(	NULL
34	NULL
)	NULL
,	NULL
Rac	NULL
(	NULL
35	NULL
)	NULL
,	NULL
Cded42Hs	NULL
,	NULL
SLP-76	NULL
(	NULL
36	NULL
,	NULL
37	NULL
)	NULL
,	NULL
PLCy1	NULL
,	NULL
and	NULL
the	NULL
TcR	NULL
{	NULL
chain	NULL
(	NULL
388	NULL
,	NULL
39	NULL
)	NULL
failed	NULL
to	NULL
show	NULL
any	NULL
differences	NULL
.	NULL

It	NULL
is	NULL
unlikely	NULL
that	NULL
p85	NULL
acts	NULL
through	NULL
Cbl	NULL
,	NULL
because	NULL
a	NULL
transforming	NULL
Cbl	NULL
mutant	NULL
that	NULL
constitutively	NULL
activated	NULL
NFAT	NULL
(	NULL
70/23	NULL
)	NULL
still	NULL
did	NULL
so	NULL
even	NULL
after	NULL
its	NULL
binding	NULL
to	NULL
PI3-K	NULL
was	NULL
disrupted	NULL
by	NULL
a	NULL
point	NULL
mutation	NULL
(	NULL
40	NULL
)	NULL
.	NULL

A	NULL
connection	NULL
between	NULL
PI3-K	NULL
and	NULL
Ras	NULL
has	NULL
been	NULL
demonstrated	NULL
PI	NULL
(	NULL
3	NULL
)	NULL
P	NULL
OKT3	NULL
phospho-Erk2	NULL
14487	NULL
origin	NULL
-	NULL
Â©	NULL
d	NULL
#	NULL
%	NULL
#	NULL
3	NULL
min	NULL
a	NULL
*	NULL
3	NULL
3	NULL
h	NULL
nM	NULL
Wortm	NULL
.	NULL

o	NULL
-	NULL
o	NULL
40	NULL
100	NULL
103	NULL
104	NULL
o	NULL
o	NULL
40	NULL
400	NULL
403	NULL
404	NULL
3x105	NULL
wat	NULL
#	NULL
k	NULL
ins	NULL
-=	NULL
2x105	NULL
105	NULL
luciferase	NULL
activity	NULL
0	NULL
in	NULL
several	NULL
reports	NULL
.	NULL

Ras	NULL
can	NULL
bind	NULL
p110	NULL
in	NULL
a	NULL
GTP-dependent	NULL
manner	NULL
,	NULL
and	NULL
transfection	NULL
of	NULL
Ras	NULL
resulted	NULL
in	NULL
an	NULL
elevation	NULL
of	NULL
3-phosphoinositides	NULL
,	NULL
whereas	NULL
dominant	NULL
negative	NULL
RasN17	NULL
inhibited	NULL
production	NULL
of	NULL
3-phosphoinositides	NULL
(	NULL
21	NULL
)	NULL
.	NULL

Together	NULL
with	NULL
the	NULL
finding	NULL
that	NULL
GTP-Ras	NULL
could	NULL
activate	NULL
PI3-K	NULL
(	NULL
41	NULL
)	NULL
,	NULL
this	NULL
argues	NULL
for	NULL
a	NULL
role	NULL
of	NULL
Ras	NULL
upstream	NULL
of	NULL
PI3-K.	NULL
On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
constitutively	NULL
active	NULL
PI3-K	NULL
increased	NULL
the	NULL
amount	NULL
of	NULL
GTP-bound	NULL
Ras	NULL
and	NULL
activated	NULL
the	NULL
c-fos	NULL
promoter	NULL
,	NULL
and	NULL
coexpression	NULL
of	NULL
dominant	NULL
negative	NULL
Ras	NULL
blocked	NULL
c-fos	NULL
activation	NULL
(	NULL
42	NULL
)	NULL
.	NULL

Ras	NULL
is	NULL
also	NULL
playing	NULL
a	NULL
major	NULL
role	NULL
in	NULL
TcR-induced	NULL
NFAT	NULL
activation	NULL
(	NULL
43	NULL
,	NULL
44	NULL
)	NULL
.	NULL

We	NULL
were	NULL
wondering	NULL
if	NULL
functional	NULL
Ras	NULL
was	NULL
required	NULL
for	NULL
the	NULL
p85SNC-medi-ated	NULL
increase	NULL
in	NULL
NFAT	NULL
activity	NULL
,	NULL
and	NULL
cotransfection	NULL
of	NULL
RasN17	NULL
showed	NULL
that	NULL
this	NULL
was	NULL
indeed	NULL
the	NULL
case	NULL
.	NULL

This	NULL
would	NULL
place	NULL
Ras	NULL
downstream	NULL
of	NULL
PI3-K	NULL
in	NULL
T	NULL
cells	NULL
,	NULL
but	NULL
does	NULL
not	NULL
exclude	NULL
a	NULL
role	NULL
also	NULL
upstream	NULL
of	NULL
PI3-K	NULL
.	NULL

Although	NULL
we	NULL
presently	NULL
do	NULL
not	NULL
know	NULL
the	NULL
molecular	NULL
mechanism	NULL
by	NULL
which	NULL
p85	NULL
activates	NULL
NFAT	NULL
,	NULL
we	NULL
found	NULL
that	NULL
several	NULL
p85	NULL
constructs	NULL
acted	NULL
on	NULL
NFAT	NULL
activation	NULL
via	NULL
the	NULL
Ras/PKC	NULL
pathway	NULL
.	NULL

Activation	NULL
of	NULL
NFAT	NULL
depends	NULL
on	NULL
two	NULL
signals	NULL
;	NULL
calcium/cal-cineurin	NULL
is	NULL
required	NULL
for	NULL
nuclear	NULL
translocation	NULL
of	NULL
NFATp	NULL
,	NULL
and	NULL
Ras/PKC	NULL
is	NULL
required	NULL
for	NULL
induction	NULL
of	NULL
AP-1	NULL
.	NULL

Those	NULL
p85	NULL
alleles	NULL
that	NULL
increased	NULL
the	NULL
basal	NULL
NFAT	NULL
level	NULL
also	NULL
synergized	NULL
with	NULL
ionomycin	NULL
(	NULL
but	NULL
not	NULL
with	NULL
PMA	NULL
)	NULL
,	NULL
which	NULL
suggests	NULL
that	NULL
they	NULL
mimicked	NULL
a	NULL
process	NULL
in	NULL
the	NULL
Ras/PKC	NULL
pathway	NULL
to	NULL
cooperate	NULL
with	NULL
calcium/	NULL
calcineurin	NULL
.	NULL

And	NULL
while	NULL
cyclosporin	NULL
A	NULL
effectively	NULL
inhibited	NULL
NFAT	NULL
activation	NULL
,	NULL
coexpression	NULL
of	NULL
inhibitory	NULL
p85	NULL
constructs	NULL
caused	NULL
an	NULL
additional	NULL
decrease	NULL
in	NULL
NFAT	NULL
activity	NULL
,	NULL
most	NULL
likely	NULL
by	NULL
interfering	NULL
with	NULL
the	NULL
Ras/PKC	NULL
pathway	NULL
.	NULL

Finally	NULL
,	NULL
the	NULL
finding	NULL
that	NULL
RasN17	NULL
blocked	NULL
p85NC-induced	NULL
NFAT	NULL
activation	NULL
provides	NULL
additional	NULL
evidence	NULL
for	NULL
a	NULL
function	NULL
of	NULL
p85	NULL
in	NULL
the	NULL
Ras	NULL
pathway	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
our	NULL
results	NULL
indicate	NULL
that	NULL
p85	NULL
with	NULL
its	NULL
multiple	NULL
domains	NULL
plays	NULL
an	NULL
important	NULL
and	NULL
complex	NULL
role	NULL
in	NULL
TcR-induced	NULL
gene	NULL
activation	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Kapeller	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Cantley	NULL
,	NULL
L.	NULL
C.	NULL
(	NULL
1994	NULL
)	NULL
Bioessays	NULL
16	NULL
,	NULL
565-576	NULL
2	NULL
.	NULL

Ward	NULL
,	NULL
S.	NULL
G.	NULL
,	NULL
Ley	NULL
,	NULL
S.	NULL
C.	NULL
,	NULL
MacPhee	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Cantrell	NULL
,	NULL
D.	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

22	NULL
,	NULL
45-49	NULL
3	NULL
.	NULL

Toker	NULL
,	NULL
A.	NULL
,	NULL
Meyer	NULL
,	NULL
M.	NULL
,	NULL
Reddy	NULL
,	NULL
K.	NULL
K.	NULL
,	NULL
Falck	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
Angja	NULL
,	NULL
R.	NULL
,	NULL
Angja	NULL
,	NULL
S.	NULL
,	NULL
Parra	NULL
,	NULL
A.	NULL
,	NULL
Burns	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Ballas	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
and	NULL
Cantley	NULL
,	NULL
L.	NULL
C.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269	NULL
,	NULL
32358-32367	NULL
4	NULL
.	NULL

Nakanishi	NULL
,	NULL
H.	NULL
,	NULL
Brewer	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
and	NULL
Exton	NULL
,	NULL
J.	NULL
H.	NULL
(	NULL
1993	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268	NULL
,	NULL
13-16	NULL
5	NULL
.	NULL

Akimoto	NULL
,	NULL
K.	NULL
,	NULL
Takahashi	NULL
,	NULL
R.	NULL
,	NULL
Moriya	NULL
,	NULL
S.	NULL
,	NULL
Nishioka	NULL
,	NULL
N.	NULL
,	NULL
Takayanagi	NULL
,	NULL
J.	NULL
,	NULL
Kimura	NULL
,	NULL
K.	NULL
,	NULL
Fukui	NULL
,	NULL
Y.	NULL
,	NULL
Osada	NULL
,	NULL
S.	NULL
,	NULL
Mizuno	NULL
,	NULL
K.	NULL
,	NULL
Hirai	NULL
,	NULL
S.	NULL
,	NULL
Kazlauskas	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Ohno	NULL
,	NULL
S.	NULL
(	NULL
1996	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

15	NULL
,	NULL
788-798	NULL
6	NULL
.	NULL

Burgering	NULL
,	NULL
B.	NULL
M.	NULL
,	NULL
and	NULL
Coffer	NULL
,	NULL
P.	NULL
J	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Nature	NULL
876	NULL
,	NULL
599-602	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
/810-0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wo	NULL
;	NULL
popeoumog	NULL
14488	NULL
7	NULL
.	NULL

Franke	NULL
,	NULL
T.	NULL
F.	NULL
,	NULL
Yang	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
Chan	NULL
,	NULL
T.	NULL
O.	NULL
,	NULL
Datta	NULL
,	NULL
K.	NULL
,	NULL
Kazlauskas	NULL
,	NULL
A.	NULL
,	NULL
Morrison	NULL
,	NULL
D.	NULL
K.	NULL
,	NULL
Kaplan	NULL
,	NULL
D.	NULL
R.	NULL
,	NULL
and	NULL
Tsichlis	NULL
,	NULL
P.	NULL
N.	NULL
(	NULL
1995	NULL
)	NULL
Cell	NULL
81	NULL
,	NULL
727-786	NULL
8	NULL
.	NULL

Escobedo	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Navankasattusas	NULL
,	NULL
S.	NULL
,	NULL
Kavanaugh	NULL
,	NULL
W.	NULL
M.	NULL
,	NULL
Milfay	NULL
,	NULL
D.	NULL
,	NULL
Fried	NULL
,	NULL
V.	NULL
A.	NULL
,	NULL
and	NULL
Williams	NULL
,	NULL
L.	NULL
T.	NULL
(	NULL
1991	NULL
)	NULL
Cell	NULL
65	NULL
,	NULL
75-82	NULL
9	NULL
.	NULL

Otsu	NULL
,	NULL
M.	NULL
,	NULL
Hiles	NULL
,	NULL
I.	NULL
,	NULL
Gout	NULL
,	NULL
L.	NULL
,	NULL
Fry	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Ruiz	NULL
Larrea	NULL
,	NULL
F.	NULL
,	NULL
Panayotou	NULL
,	NULL
G.	NULL
,	NULL
Thompson	NULL
,	NULL
A.	NULL
,	NULL
Dhand	NULL
,	NULL
R.	NULL
,	NULL
Hsuan	NULL
,	NULL
J.	NULL
,	NULL
Totty	NULL
,	NULL
N.	NULL
,	NULL
Smith	NULL
,	NULL
A.	NULL
D.	NULL
,	NULL
Morgan	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
Courtneidge	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
Parker	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
and	NULL
Waterfield	NULL
,	NULL
M.	NULL
D.	NULL
(	NULL
1991	NULL
)	NULL
Cell	NULL
65	NULL
,	NULL
91-104	NULL
10	NULL
.	NULL

Skolnik	NULL
,	NULL
E.	NULL
Y.	NULL
,	NULL
Margolis	NULL
,	NULL
B.	NULL
,	NULL
Mohammadi	NULL
,	NULL
M.	NULL
,	NULL
Lowenstein	NULL
,	NULL
E.	NULL
,	NULL
Fischer	NULL
,	NULL
R.	NULL
,	NULL
Drepps	NULL
,	NULL
A.	NULL
,	NULL
Ullrich	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Schlessinger	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Cell	NULL
65	NULL
,	NULL
83-90	NULL
11	NULL
.	NULL

Hiles	NULL
,	NULL
I.	NULL
D.	NULL
,	NULL
Otsu	NULL
,	NULL
M.	NULL
,	NULL
Volinia	NULL
,	NULL
S.	NULL
,	NULL
Fry	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Gout	NULL
,	NULL
I.	NULL
,	NULL
Dhand	NULL
,	NULL
R.	NULL
,	NULL
Panayotou	NULL
,	NULL
G.	NULL
,	NULL
Ruiz	NULL
Larrea	NULL
,	NULL
F.	NULL
,	NULL
Thompson	NULL
,	NULL
A.	NULL
,	NULL
Totty	NULL
,	NULL
N.	NULL
F.	NULL
,	NULL
Hsuan	NULL
,	NULL
J.	NULL
,	NULL
Courtneidge	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
Parker	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
and	NULL
Waterfield	NULL
,	NULL
M.	NULL
D.	NULL
(	NULL
1992	NULL
)	NULL
Cell	NULL
70	NULL
,	NULL
419-429	NULL
12	NULL
.	NULL

Dhand	NULL
,	NULL
R.	NULL
,	NULL
Hara	NULL
,	NULL
K.	NULL
,	NULL
Hiles	NULL
,	NULL
L.	NULL
,	NULL
Bax	NULL
,	NULL
B.	NULL
,	NULL
Gout	NULL
,	NULL
I.	NULL
,	NULL
Panayotou	NULL
,	NULL
G.	NULL
,	NULL
Fry	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Yonezawa	NULL
,	NULL
K.	NULL
,	NULL
Kasuga	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Waterfield	NULL
,	NULL
M.	NULL
D.	NULL
(	NULL
1994	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

13	NULL
,	NULL
511-521	NULL
13	NULL
.	NULL

Hu	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Schlessinger	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14	NULL
,	NULL
2577-2583	NULL
14	NULL
.	NULL

Holt	NULL
,	NULL
K.	NULL
H.	NULL
,	NULL
Olson	NULL
,	NULL
L.	NULL
,	NULL
Moye	NULL
,	NULL
R.	NULL
W.	NULL
,	NULL
and	NULL
Pessin	NULL
,	NULL
J.	NULL
E.	NULL
(	NULL
1994	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14	NULL
,	NULL
42-49	NULL
15	NULL
.	NULL

Klippel	NULL
,	NULL
A.	NULL
,	NULL
Escobedo	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Hirano	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Williams	NULL
,	NULL
L.	NULL
T.	NULL
(	NULL
1994	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14	NULL
,	NULL
2675-2685	NULL
16	NULL
.	NULL

Dhand	NULL
,	NULL
R.	NULL
,	NULL
Hiles	NULL
,	NULL
I.	NULL
,	NULL
Panayotou	NULL
,	NULL
G.	NULL
,	NULL
Roche	NULL
,	NULL
S.	NULL
,	NULL
Fry	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Gout	NULL
,	NULL
I.	NULL
,	NULL
Totty	NULL
,	NULL
N.	NULL
F.	NULL
,	NULL
Truong	NULL
,	NULL
O.	NULL
,	NULL
Vicendo	NULL
,	NULL
P.	NULL
,	NULL
Yonezawa	NULL
,	NULL
K.	NULL
,	NULL
Kasuga	NULL
,	NULL
M.	NULL
,	NULL
Courtneidge	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
and	NULL
Waterfield	NULL
,	NULL
M.	NULL
D.	NULL
(	NULL
1994	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

18	NULL
,	NULL
522-533	NULL
17	NULL
.	NULL

Klippel	NULL
,	NULL
A.	NULL
,	NULL
Reinhard	NULL
,	NULL
C.	NULL
,	NULL
Kavanaugh	NULL
,	NULL
W.	NULL
M.	NULL
,	NULL
Apell	NULL
,	NULL
G.	NULL
,	NULL
Escobedo	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
and	NULL
Williams	NULL
,	NULL
L.	NULL
T.	NULL
(	NULL
1996	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

16	NULL
,	NULL
4117-4127	NULL
18	NULL
.	NULL

Pleiman	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
Hertz	NULL
,	NULL
W.	NULL
M.	NULL
,	NULL
and	NULL
Cambier	NULL
,	NULL
J.	NULL
C.	NULL
(	NULL
1994	NULL
)	NULL
Science	NULL
268	NULL
,	NULL
1609-1612	NULL
19	NULL
.	NULL

Carpenter	NULL
,	NULL
C.	NULL
L.	NULL
,	NULL
Auger	NULL
,	NULL
K.	NULL
R.	NULL
,	NULL
Chanudhuri	NULL
,	NULL
M.	NULL
,	NULL
Yoakim	NULL
,	NULL
M.	NULL
,	NULL
Schaffhausen	NULL
,	NULL
B.	NULL
,	NULL
Shoelson	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Cantley	NULL
,	NULL
L.	NULL
C.	NULL
(	NULL
1993	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268	NULL
,	NULL
9478-9483	NULL
20	NULL
.	NULL

Backer	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Myers	NULL
,	NULL
M.	NULL
G.	NULL
,	NULL
Jr.	NULL
,	NULL
Shoelson	NULL
,	NULL
S.	NULL
E.	NULL
,	NULL
Chin	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Sun	NULL
,	NULL
X.	NULL
J.	NULL
,	NULL
Miralpeix	NULL
,	NULL
M.	NULL
,	NULL
Hu	NULL
,	NULL
P.	NULL
,	NULL
Margolis	NULL
,	NULL
B.	NULL
,	NULL
Skolnik	NULL
,	NULL
E.	NULL
Y.	NULL
,	NULL
Schlessinger	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
White	NULL
,	NULL
M.	NULL
F.	NULL
(	NULL
1992	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

11	NULL
,	NULL
3469-3479	NULL
21	NULL
.	NULL

Rodriguez	NULL
Viciana	NULL
,	NULL
P.	NULL
,	NULL
Warne	NULL
,	NULL
P.	NULL
H.	NULL
,	NULL
Dhand	NULL
,	NULL
R.	NULL
,	NULL
Vanhaesebroeck	NULL
,	NULL
B.	NULL
,	NULL
Gout	NULL
,	NULL
I.	NULL
,	NULL
Fry	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Waterfield	NULL
,	NULL
M.	NULL
D.	NULL
,	NULL
and	NULL
Downward	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Nature	NULL
870	NULL
,	NULL
527-582	NULL
22	NULL
.	NULL

Von	NULL
Willebrand	NULL
,	NULL
M.	NULL
,	NULL
Jascur	NULL
,	NULL
T.	NULL
,	NULL
Bonnefoy	NULL
Berard	NULL
,	NULL
N.	NULL
,	NULL
Yano	NULL
,	NULL
H.	NULL
,	NULL
Altman	NULL
,	NULL
A.	NULL
,	NULL
Matsuda	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
Mustelin	NULL
,	NULL
T.	NULL
(	NULL
1996	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Biochem	NULL
.	NULL

295	NULL
,	NULL
828-835	NULL
23	NULL
.	NULL

Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
15	NULL
,	NULL
274-281	NULL
24	NULL
.	NULL

Nel	NULL
,	NULL
A.	NULL
E.	NULL
,	NULL
Hanekom	NULL
,	NULL
C.	NULL
,	NULL
Rheeder	NULL
,	NULL
A.	NULL
,	NULL
Williams	NULL
,	NULL
K.	NULL
,	NULL
Pollack	NULL
,	NULL
S.	NULL
,	NULL
Katz	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Landreth	NULL
,	NULL
G.	NULL
E.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

144	NULL
,	NULL
2683-2689	NULL
25	NULL
.	NULL

Cantrell	NULL
,	NULL
D.	NULL
(	NULL
1996	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

14	NULL
,	NULL
259-274	NULL
26	NULL
27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

PI3-K	NULL
in	NULL
NFAT	NULL
Activation	NULL
.	NULL

O'Kecfe	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
Tamura	NULL
,	NULL
J.	NULL
,	NULL
Kincaid	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
Tocci	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
and	NULL
O'Neill	NULL
,	NULL
E.	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Nature	NULL
857	NULL
,	NULL
692-694	NULL
Clipstone	NULL
,	NULL
N.	NULL
A.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1992	NULL
)	NULL
Nature	NULL
857	NULL
,	NULL
695-697	NULL
Yamauchi	NULL
,	NULL
K.	NULL
,	NULL
Holt	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Pessin	NULL
,	NULL
J.	NULL
E.	NULL
(	NULL
1998	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268	NULL
,	NULL
14597-14600	NULL
Ui	NULL
,	NULL
M.	NULL
,	NULL
Okada	NULL
,	NULL
T.	NULL
,	NULL
Hazeki	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Hazeki	NULL
,	NULL
O	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Trends	NULL
Biochem	NULL
.	NULL

Sci	NULL
.	NULL

20	NULL
,	NULL
303-307	NULL
Songyang	NULL
,	NULL
Z.	NULL
,	NULL
Shoelson	NULL
,	NULL
S.	NULL
E.	NULL
,	NULL
Chaudhuri	NULL
,	NULL
M.	NULL
,	NULL
Gish	NULL
,	NULL
G.	NULL
,	NULL
Pawson	NULL
,	NULL
T.	NULL
,	NULL
Haser	NULL
,	NULL
W.	NULL
G.	NULL
,	NULL
King	NULL
,	NULL
F.	NULL
,	NULL
Roberts	NULL
,	NULL
T.	NULL
,	NULL
Ratnofsky	NULL
,	NULL
S.	NULL
,	NULL
Lechleider	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
Neel	NULL
,	NULL
B.	NULL
G.	NULL
,	NULL
Birge	NULL
,	NULL
R.	NULL
B.	NULL
,	NULL
Fajardo	NULL
,	NULL
J.	NULL
E.	NULL
,	NULL
Chou	NULL
,	NULL
M.	NULL
M.	NULL
,	NULL
Hanafusa	NULL
,	NULL
H.	NULL
,	NULL
Schaffhausen	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
Cantley	NULL
,	NULL
L.	NULL
C.	NULL
(	NULL
1998	NULL
)	NULL
Cell	NULL
72	NULL
,	NULL
767-778	NULL
Mellroy	NULL
,	NULL
J.	NULL
,	NULL
Chen	NULL
,	NULL
D.	NULL
,	NULL
Wjasow	NULL
,	NULL
C.	NULL
,	NULL
Michaeli	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Backer	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

17	NULL
,	NULL
248-255	NULL
Fukazawa	NULL
,	NULL
T.	NULL
,	NULL
Reedquist	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
Trub	NULL
,	NULL
T.	NULL
,	NULL
Soltoff	NULL
,	NULL
S.	NULL
,	NULL
Panchamoorthy	NULL
,	NULL
G.	NULL
,	NULL
Druker	NULL
,	NULL
B.	NULL
,	NULL
Cantley	NULL
,	NULL
L.	NULL
,	NULL
Shoelson	NULL
,	NULL
S.	NULL
E.	NULL
,	NULL
and	NULL
Band	NULL
,	NULL
H.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270	NULL
,	NULL
19141-19150	NULL
Meisner	NULL
,	NULL
H.	NULL
,	NULL
Conway	NULL
,	NULL
B.	NULL
R.	NULL
,	NULL
Hartley	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Czech	NULL
,	NULL
M.	NULL
P.	NULL
(	NULL
1995	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15	NULL
,	NULL
3571-3578	NULL
Wang	NULL
,	NULL
J.	NULL
,	NULL
Auger	NULL
,	NULL
K.	NULL
R.	NULL
,	NULL
Jarvis	NULL
,	NULL
L.	NULL
,	NULL
Shi	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
Roberts	NULL
,	NULL
T.	NULL
M.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270	NULL
,	NULL
12774-12780	NULL
Tolias	NULL
,	NULL
K.	NULL
F.	NULL
,	NULL
Cantley	NULL
,	NULL
L.	NULL
C.	NULL
,	NULL
and	NULL
Carpenter	NULL
,	NULL
C.	NULL
L.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270	NULL
,	NULL
17656-17659	NULL
Fang	NULL
,	NULL
N.	NULL
,	NULL
Motto	NULL
,	NULL
D.	NULL
G.	NULL
,	NULL
Ross	NULL
,	NULL
S.	NULL
E.	NULL
,	NULL
and	NULL
Koretzky	NULL
,	NULL
G.	NULL
A	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

157	NULL
,	NULL
3769-3773	NULL
Motto	NULL
,	NULL
D.	NULL
G.	NULL
,	NULL
Ross	NULL
,	NULL
S.	NULL
E.	NULL
,	NULL
Wu	NULL
,	NULL
J.	NULL
,	NULL
Hendricks	NULL
,	NULL
T.	NULL
L.	NULL
,	NULL
and	NULL
Koretzky	NULL
,	NULL
G.	NULL
A	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

188	NULL
,	NULL
1937-1943	NULL
Carrera	NULL
,	NULL
A.	NULL
C.	NULL
,	NULL
Rodriguez	NULL
Borlado	NULL
,	NULL
L.	NULL
,	NULL
Martinez	NULL
Alonso	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Merida	NULL
,	NULL
I	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269	NULL
,	NULL
19435-19440	NULL
Exley	NULL
,	NULL
M.	NULL
,	NULL
Varticovski	NULL
,	NULL
L.	NULL
,	NULL
Peter	NULL
,	NULL
M.	NULL
,	NULL
Sancho	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Terhorst	NULL
,	NULL
C.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269	NULL
,	NULL
15140-15146	NULL
Liu	NULL
,	NULL
Y.-C.	NULL
,	NULL
Elly	NULL
,	NULL
C.	NULL
,	NULL
Langdon	NULL
,	NULL
W.	NULL
Y.	NULL
,	NULL
and	NULL
Altman	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

272	NULL
,	NULL
168-173	NULL
Rodriguez	NULL
Viciana	NULL
,	NULL
P.	NULL
,	NULL
Warne	NULL
,	NULL
P.	NULL
H.	NULL
,	NULL
Vanhaesebroeck	NULL
,	NULL
B.	NULL
,	NULL
Waterfield	NULL
,	NULL
M.	NULL
D.	NULL
,	NULL
and	NULL
Downward	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

15	NULL
,	NULL
2442-2451	NULL
Hu	NULL
,	NULL
Q.	NULL
,	NULL
Klippel	NULL
,	NULL
A.	NULL
,	NULL
Muslin	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
Fant	NULL
]	NULL
,	NULL
W.	NULL
J.	NULL
,	NULL
and	NULL
Williams	NULL
,	NULL
L.	NULL
T.	NULL
(	NULL
1995	NULL
)	NULL
Science	NULL
268	NULL
,	NULL
100-102	NULL
Woodrow	NULL
,	NULL
M.	NULL
,	NULL
Clipstone	NULL
,	NULL
N.	NULL
A.	NULL
,	NULL
and	NULL
Cantrell	NULL
,	NULL
D.	NULL
(	NULL
1998	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

178	NULL
,	NULL
1517-1522	NULL
Woodrow	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Rayter	NULL
,	NULL
S.	NULL
,	NULL
Downward	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Cantrell	NULL
,	NULL
D.	NULL
A	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

150	NULL
,	NULL
3858-3861	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
/810-0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wo	NULL
;	NULL
popeoumog	NULL
Involvement	NULL
of	NULL
Phosphatidylinositol	NULL
3-Kinase	NULL
in	NULL
NFAT	NULL
Activation	NULL
in	NULL
T	NULL
Cells	NULL
Thomas	NULL
Jascur	NULL
,	NULL
Jennifer	NULL
Gilman	NULL
and	NULL
Tomas	NULL
Mustelin	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

1997	NULL
,	NULL
272:14483-14488.	NULL
doi	NULL
:	NULL
10.1074/jb0.272.22.14483	NULL
Access	NULL
the	NULL
most	NULL
updated	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
http	NULL
:	NULL
/www.jbe.org/content/272/22/1	NULL
4483	NULL
Alerts	NULL
:	NULL
Â«	NULL
When	NULL
this	NULL
article	NULL
is	NULL
cited	NULL
Â«	NULL
When	NULL
a	NULL
correction	NULL
for	NULL
this	NULL
article	NULL
is	NULL
posted	NULL
Click	NULL
here	NULL
to	NULL
choose	NULL
from	NULL
all	NULL
of	NULL
JBC	NULL
's	NULL
e-mail	NULL
alerts	NULL
This	NULL
article	NULL
cites	NULL
44	NULL
references	NULL
,	NULL
23	NULL
of	NULL
which	NULL
can	NULL
be	NULL
accessed	NULL
free	NULL
at	NULL
http	NULL
:	NULL
//www	NULL
4483.	NULL
full.html	NULL
#	NULL
ref-list-1	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL

